FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Daniel Von Hoff

Research Profile

Chemicals & Drugs

Disorders

Activities & Behaviors

Drug Evaluation

Procedures

Anatomy

Concepts & Ideas

Living Beings

Mouse

Physiology

Cell Divisions

Co-author Network

Publications

TOP 3
Muhammad Wasif Saif; C Storgard; D Toft; F Burrows; Tomislav Dragovich; C Erlichman; D Mendelson; Daniel Von Hoff
Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors.
David Craig; Francisco M De La Vega; Jennifer Dinh; Linh Hoang; Tyler Izatt; Jeffrey A Kiefer; Julie Koeman; Ahmet Kurdoglu; Tracy M Moses; Spyro Mousses; Cynthia R Osborne; Joyce A O'Shaughnessy; Onur Sakarya; Bodour Salhia; Asim Siddiqui; Shripad Sinari; Anthony W Tolcher; Jeffrey M. Trent; Daniel Von Hoff; Shukmei Wong; Cristi L Aitelli; Jessica Aldrich; Angela Baker; Catalin Barbacioru; Paul R Billings; Joanne L Blum; Alexis Christoforides; John D Carpten
Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities.
Toni Farley; Jeff Kiefer; Preston Lee; Jeffrey M. Trent; Daniel Von Hoff; Charles Colbourn; Spyro Mousses
The BioIntelligence Framework: a new computational platform for biomedical knowledge computing.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Daniel Von Hoff (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Muhammad Wasif Saif; C Storgard; D Toft; F Burrows; Tomislav Dragovich; C Erlichman; D Mendelson; Daniel Von Hoff
Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors.
Cancer chemotherapy and pharmacology 2013;71(5):1345-55.
2013: David Craig; Francisco M De La Vega; Jennifer Dinh; Linh Hoang; Tyler Izatt; Jeffrey A Kiefer; Julie Koeman; Ahmet Kurdoglu; Tracy M Moses; Spyro Mousses; Cynthia R Osborne; Joyce A O'Shaughnessy; Onur Sakarya; Bodour Salhia; Asim Siddiqui; Shripad Sinari; Anthony W Tolcher; Jeffrey M. Trent; Daniel Von Hoff; Shukmei Wong; Cristi L Aitelli; Jessica Aldrich; Angela Baker; Catalin Barbacioru; Paul R Billings; Joanne L Blum; Alexis Christoforides; John D Carpten
Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities.
Molecular cancer therapeutics 2013;12(1):104-16.
2013: Toni Farley; Jeff Kiefer; Preston Lee; Jeffrey M. Trent; Daniel Von Hoff; Charles Colbourn; Spyro Mousses
The BioIntelligence Framework: a new computational platform for biomedical knowledge computing.
Journal of the American Medical Informatics Association : JAMIA 2013;20(1):128-33.
2012: Jeffrey Hrkach; Philip W Kantoff; Robert Langer; Patricia M LoRusso; Susan Low; Kevin McDonnell; Erick Peeke; Beadle Retnarajan; Abhimanyu Sabnis; Edward Schnipper; Jeffrey J Song; Young Ho Song; Jason Summa; Christopher Sweeney; Douglas Tompsett; Greg Troiano; Tina Van Geen Hoven; Daniel Von Hoff; Jim Wright; Elizaveta Andrianova; Jason Auer; Neil H Bander; Tarikh Campbell; David De Witt; Omid C Farokhzad; Michael Figa; Maria Figueiredo; Allen Horhota; Mir Mukkaram Ali; Stephen Zale
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.
Science translational medicine 2012;4(128):128ra39.
2012: Tara Holley; Christine A Iacobuzio-Donahue; Christophe Legendre; Elizabeth Lenkiewicz; Ann E McCullough; Barbara Pockaj; Cyrill A Rentsch; Christian Ruiz; Mark Stapleton; Waibhav Tembe; Daniel Von Hoff; Lukas Bubendorf; John D Carpten; David Craig; Heather E Cunliffe; Lisa Evers; Joel R Gsponer; Doug Amorese; Michael T Barrett
Deep clonal profiling of formalin fixed paraffin embedded clinical samples.
PloS one 2012;7(11):e50586.
2012: Winnie S Liang; Lori Phillips; Richard Posner; Ramesh K Ramanathan; Shripad Sinari; A Keith Stewart; Edward C Stites; Waibhav Tembe; Glen J Weiss; Jessica Aldrich; Angela Baker; Michael Barrett; Hollie Benson; Mitesh J Borad; Esteban Braggio; John D Carpten; Alexis Christoforides; David Craig; Micheal J Demeure; Jan B Egan; Rafael Fonseca; Haiyong Han; Galen H Hostetter; Tyler Izatt; Jeffrey A Kiefer; Ahmet Kurdoglu; Douglas Lake; Christophe Legendre; Daniel Von Hoff
Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing.
PloS one 2012;7(10):e43192.
2011: Aditi A Bapat; Galen Hostetter; Daniel Von Hoff; Haiyong Han
Perineural invasion and associated pain in pancreatic cancer.
Nature reviews. Cancer 2011;11(10):695-707.
2011: Naoki Mine; Naoya Saito; Chikako Suda; Daniel Von Hoff; Sayaka Yamamoto; Satoshi Yamazaki; Machiyo Ishigaki; Donald W Kufe; Takumi Kawabe
CBP501-calmodulin binding contributes to sensitizing tumor cells to cisplatin and bleomycin.
Molecular cancer therapeutics 2011;10(10):1929-38.
2011: Daruka Mahadevan; R Plummer; C Pretzinger; D Rensvold; D M Smith; M S Squires; Daniel Von Hoff; J Adams; Tomislav Dragovich; S Kurtin; V Lock; H Calvert
A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(9):2137-43.
2011: Christian Ruiz; Michael Shen; Jeffrey M. Trent; Daniel Von Hoff; Tobias Zellweger; Lukas Bubendorf; John D Carpten; Micheal J Demeure; Lisa Evers; Tara Holley; Michael A Hollingsworth; Jeff Kiefer; Elizabeth Lenkiewicz; Spyro Mousses; Donna Prunkard; Peter S Rabinovitch; Alex Robeson; Michael T Barrett
Advancing a clinically relevant perspective of the clonal nature of cancer.
Proceedings of the National Academy of Sciences of the United States of America 2011;108(29):12054-9.
2011: Raoul Tibes; Daniel Von Hoff; Jay H Yim; R Curtis Bay; Martin A Benjamin; Raysenia L James; Barbara F Piper; Ramesh K Ramanathan; Jessica A Smith; Mitesh J Borad
Patient willingness to undergo pharmacodynamic and pharmacokinetic tests in early phase oncology trials.
Cancer 2011;117(14):3276-83.
2011: Michael S Ewer; Daniel Von Hoff; Robert S Benjamin
A historical perspective of anthracycline cardiotoxicity.
Heart failure clinics 2011;7(3):363-72.
2011: Meredith C Henderson; Spyro Mousses; Jeffrey M. Trent; Daniel Von Hoff; Shilpi Arora; Ashish Choudhary; Irma M Gonzales; David Azorsa
High-throughput RNAi screening identifies a role for TNK1 in growth and survival of pancreatic cancer cells.
Molecular cancer research : MCR 2011;9(6):724-32.
2011: Geoffrey I Shapiro; Raoul Tibes; Michael S Gordon; Bryan Y Wong; Joseph Paul Eder; Mitesh J Borad; David S Mendelson; Nicholas J Vogelzang; Bruno R Bastos; Glen J Weiss; Cristian Fernandez; William Sutherland; Hitoshi Sato; William E Pierceall; David Weaver; Scott Slough; Ernesto Wasserman; Donald W Kufe; Daniel Von Hoff; Takumi Kawabe; Sunil Sharma
Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(10):3431-42.
2011: Caroline H Diep; Ruben M Munoz; Ashish Choudhary; Daniel Von Hoff; Haiyong Han
Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(9):2744-56.
2011: Patricia M LoRusso; Charles Rudin; Josina C Reddy; Raoul Tibes; Glen J Weiss; Mitesh J Borad; CHRISTINE HANN; Julie R Brahmer; Ilsung Chang; Walter C Darbonne; Richard A Graham; Kenn L Zerivitz; Jennifer A Low; Daniel Von Hoff
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(8):2502-11.
2011: Richard A Graham; Bert L Lum; Sravanthi Cheeti; Jin Yan Jin; Karin Jorga; Daniel Von Hoff; Charles Rudin; Josina C Reddy; Jennifer A Low; Patricia M LoRusso
Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(8):2512-20.
2011: Ramesh K Ramanathan; James Abbruzzese; Tomislav Dragovich; Lynn Kirkpatrick; Jose M Guillen; Amanda F Baker; Linda A Pestano; Sylvan Green; Daniel Von Hoff
A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination.
Cancer chemotherapy and pharmacology 2011;67(3):503-9.
2011: Kelly A Harradine; Michelle Kassner; Donald Chow; Meraj Aziz; Daniel Von Hoff; Joffre B Baker; Holly Yin; Robert J Pelham
Functional genomics reveals diverse cellular processes that modulate tumor cell response to oxaliplatin.
Molecular cancer research : MCR 2011;9(2):173-82.
2011: Matthew D Armstrong; Daniel Von Hoff; Bruce Barber; Laura A Marlow; Christina von Roemeling; Simon J Cooper; Patrick Travis; Elizabeth Campbell; Ricardo Paz-Fumagalli; John A Copland; Gerardo Colon-Otero
An effective personalized approach to a rare tumor: prolonged survival in metastatic pancreatic acinar cell carcinoma based on genetic analysis and cell line development.
Journal of Cancer 2011;2():142-52.
2010: Daniel Von Hoff; Joseph J Stephenson; Peter Rosen; David M Loesch; Mitesh J Borad; Stephen Anthony; Gayle Jameson; Susan Brown; Nina Cantafio; Donald A Richards; Tom R Fitch; Ernesto Wasserman; Cristian Fernandez; Sylvan Green; William Sutherland; Michael Bittner; Arlet Alarcon; David Mallery; Robert J Penny
Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(33):4877-83.
2010: Micheal J Demeure; Timothy Sielaff; Larry Koep; Richard Prinz; A James Moser; Herb Zeh; Galen Hostetter; Jodi Black; Ardis Decker; Sandra Rosewell; Kimberly J Bussey; Daniel Von Hoff
Multi-institutional tumor banking: lessons learned from a pancreatic cancer biospecimen repository.
Pancreas 2010;39(7):949-54.
2010: David L Schwartz; James Bankson; Robert Lemos; Stephen Y Lai; Arun K Thittai; Yi He; Galen Hostetter; Micheal J Demeure; Daniel Von Hoff; Garth Powis
Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer.
Molecular cancer therapeutics 2010;9(7):2057-67.
2010: Glen J Weiss; Daniel Von Hoff
Hunting the hedgehog pathway.
Clinical pharmacology and therapeutics 2010;87(6):743-7.
2010: Matthew D Galsky; Tal Zaks; Habib Hassani; Linda Vocila; Guru Sonpavde; Thomas E Hutson; Daniel Von Hoff
Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics.
Investigational new drugs 2010;28(2):194-8.
2010: Glen J Weiss; Arlet Alarcon; Maqbool Halepota; Robert J Penny; Daniel Von Hoff
Molecular characterization of interdigitating dendritic cell sarcoma.
Rare tumors 2010;2(3):e50.
2010: Joshua Colvin; Michael I Monine; Ryan N Gutenkunst; William S Hlavacek; Daniel Von Hoff; Richard G Posner
RuleMonkey: software for stochastic simulation of rule-based models.
BMC bioinformatics 2010;11():404.
2010: Leonard H Goldberg; Bahar F Firoz; Glen J Weiss; Lisa Blaydorn; Gayle Jameson; Daniel Von Hoff
Basal cell nevus syndrome: a brave new world.
Archives of dermatology 2010;146(1):17-9.
2010: Archana Ramesh; Robert Trevino; Daniel Von Hoff; Seungchan Kim
Clustering context-specific gene regulatory networks.
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing 2010;():444-55.
2009: Daruka Mahadevan; Luke Dreisbach; Timothy Kristedja; Debbie Williams; Yrma Obregon; Sandy Kurtin; Daniel Von Hoff
Phase I study of fixed dose gemcitabine plus epirubicin in patients with advanced solid malignancies.
American journal of clinical oncology 2009;32(6):607-11.
2009: Steven L Warner; Bret J Stephens; Stanley Nwokenkwo; Galen Hostetter; Anastasia Sugeng; Manuel Hidalgo; Jeffrey M. Trent; Haiyong Han; Daniel Von Hoff
Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(21):6519-28.
2009: Denis Drygin; Adam Siddiqui-Jain; Sean O'Brien; Michael Schwaebe; Amy Lin; Josh Bliesath; Caroline B Ho; Chris Proffitt; Katy Trent; Jeffrey P Whitten; John K C Lim; Daniel Von Hoff; Kenna Anderes; William G Rice
Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis.
Cancer research 2009;69(19):7653-61.
2009: Daniel Von Hoff; Patricia M LoRusso; Charles Rudin; Josina C Reddy; Robert L Yauch; Raoul Tibes; Glen J Weiss; Mitesh J Borad; CHRISTINE HANN; Julie R Brahmer; Howard M Mackey; Bertram L Lum; Walter C Darbonne; James C Marsters; Frederic J de Sauvage; Jennifer A Low
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.
The New England journal of medicine 2009;361(12):1164-72.
2009: Charles Rudin; CHRISTINE HANN; John Laterra; Robert L Yauch; Christopher A Callahan; Ling Fu; THOMAS HOLCOMB; Jeremy Stinson; Stephen E Gould; Barbara Coleman; Patricia M LoRusso; Daniel Von Hoff; Frederic J de Sauvage; Jennifer A Low
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449.
The New England journal of medicine 2009;361(12):1173-8.
2009: Xuemei Cai; Phillip J Gray; Daniel Von Hoff
DNA minor groove binders: back in the groove.
Cancer treatment reviews 2009;35(5):437-50.
2009: Susan L Boone; Gayle Jameson; Daniel Von Hoff; Mario Lacouture
Blackberry-induced hand-foot skin reaction to sunitinib.
Investigational new drugs 2009;27(4):389-90.
2009: Daniel Von Hoff; Ron Korn; Spyro Mousses
Pancreatic cancer--could it be that simple? A different context of vulnerability.
Cancer cell 2009;16(1):7-8.
2009: Hong Wang; Bret Stephens; Daniel Von Hoff; Haiyong Han
Identification and characterization of a novel anticancer agent with selectivity against deleted in pancreatic cancer locus 4 (DPC4)-deficient pancreatic and colon cancer cells.
Pancreas 2009;38(5):551-7.
2009: Guru Sonpavde; Matthew D Galsky; Thomas E Hutson; Daniel Von Hoff
Patient selection for phase II trials.
American journal of clinical oncology 2009;32(2):216-9.
2009: Joshua Colvin; Michael I Monine; James R Faeder; William S Hlavacek; Daniel Von Hoff; Richard G Posner
Simulation of large-scale rule-based models.
Bioinformatics (Oxford, England) 2009;25(7):910-7.
2009: Mitesh J Borad; Hamid Saadati; Arun Lakshmipathy; Elizabeth Campbell; Patricia Hopper; Gayle Jameson; Daniel Von Hoff; M Wasif Saif
Skeletal metastases in pancreatic cancer: a retrospective study and review of the literature.
The Yale journal of biology and medicine 2009;82(1):1-6.
2009: Michael A DiMaio; Alexei Mikhailov; Conly L Rieder; Daniel Von Hoff; Robert E Palazzo
The small organic compound HMN-176 delays satisfaction of the spindle assembly checkpoint by inhibiting centrosome-dependent microtubule nucleation.
Molecular cancer therapeutics 2009;8(3):592-601.
2009: Christopher J Riley; Kevin P Engelhardt; Jose W Saldanha; Wenqing Qi; Laurence S Cooke; Yingting Zhu; Satya T Narayan; Kishore Shakalya; Kimiko Della Croce; Ivan G Georgiev; Raymond B Nagle; Harinder Garewal; Daniel Von Hoff; Daruka Mahadevan
Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer.
Cancer research 2009;69(5):1933-40.
2009: David Azorsa; Irma M Gonzales; Gargi D Basu; Ashish Choudhary; Shilpi Arora; Kristen M Bisanz; Jeff Kiefer; Meredith C Henderson; Jeffrey M. Trent; Daniel Von Hoff; Spyro Mousses
Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer.
Journal of translational medicine 2009;7():43.
2009: Meredith Henderson; Yeng-Jeng Y Shaw; Hong Wang; Haiyong Han; Laurence H Hurley; Gary Flynn; Robert T Dorr; Daniel Von Hoff
UA62784, a novel inhibitor of centromere protein E kinesin-like protein.
Molecular cancer therapeutics 2009;8(1):36-44.
2009: Martee Hensley; Karen L Hagerty; Tarun Kewalramani; Daniel M Green; Neal J Meropol; Todd H Wasserman; GARY COHEN; Bahman Emami; William J Gradishar; R Brian Mitchell; J Tate Thigpen; Andy Trotti; Daniel Von Hoff; Lynn M Schuchter
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(1):127-45.
2008: Spyro Mousses; Jeff Kiefer; Daniel Von Hoff; Jeffrey M. Trent
Using biointelligence to search the cancer genome: an epistemological perspective on knowledge recovery strategies to enable precision medical genomics.
Oncogene 2008;27 Suppl 2():S58-66.
2008: Shuaili Chen; Theresa Auletta; Ostap Dovirak; Christina Hutter; Karen Kuntz; Samira El-ftesi; Jude Kendall; Haiyong Han; Daniel Von Hoff; Raheela Ashfaq; Anirban Maitra; Christine A Iacobuzio-Donahue; Ralph Hruban; Robert Lucito
Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification.
Cancer biology & therapy 2008;7(11):1793-802.
2008: Steven L Warner; Ruben M Muñoz; David J Bearss; Paul Grippo; Haiyong Han; Daniel Von Hoff
Pdx-1-driven overexpression of aurora a kinase induces mild ductal dysplasia of pancreatic ducts near islets in transgenic mice.
Pancreas 2008;37(3):e39-44.
2008: yoganand balagurunathan; David L Morse; Galen Hostetter; Vijayalakshmi Shanmugam; Phillip Stafford; Sonsoles Shack; John Pearson; Maria Trissal; Micheal J Demeure; Daniel Von Hoff; Victor J Hruby; Robert J Gillies; Haiyong Han
Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer.
Molecular cancer therapeutics 2008;7(9):3071-80.
2008: Tomislav Dragovich; Howard Burris; Patrick Loehrer; Daniel Von Hoff; Sherry Chow; Steven Stratton; Sylvan Green; Yrma Obregon; Irene Alvarez; Michael S Gordon
Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial.
American journal of clinical oncology 2008;31(2):157-62.
2008: Steven L Warner; Bret J Stephens; Daniel Von Hoff
Tubulin-associated proteins: Aurora and Polo-like kinases as therapeutic targets in cancer.
Current oncology reports 2008;10(2):122-9.
2008: Amanda F Baker; Mei Y Koh; Ryan R Williams; Brian James; Huamin Wang; Wendy R Tate; Alfred Gallegos; Daniel Von Hoff; Haiyong Han; Garth Powis
Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer.
Pancreas 2008;36(2):178-86.
2008: Elizabeth A Stephan; Tae-Hoon Chung; Clive S Grant; Seungchan Kim; Daniel Von Hoff; Jeffrey M. Trent; Micheal J Demeure
Adrenocortical carcinoma survival rates correlated to genomic copy number variants.
Molecular cancer therapeutics 2008;7(2):425-31.
2008: Bertram Wiedenmann; Peter Malfertheiner; Helmut Friess; Paul Ritch; James Arseneau; Giovanni Mantovani; Francesco Caprioni; Eric Van Cutsem; Dirk Richel; Mark DeWitte; Ming Qi; Don Robinson; Bob Zhong; Carla De Boer; J D Lu; Uma Prabhakar; Robert Corringham; Daniel Von Hoff
A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia.
The journal of supportive oncology 2008;6(1):18-25.
2008: Bret Stephens; Haiyong Han; Galen Hostetter; Micheal J Demeure; Daniel Von Hoff
Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells.
Molecular cancer therapeutics 2008;7(1):202-10.
2008: Daniel Von Hoff; John Kuhn; Howard A Burris; Larry J Miller
Does intraosseous equal intravenous? A pharmacokinetic study.
The American journal of emergency medicine 2008;26(1):31-8.
2007: Guru Sonpavde; Ana Aparicio; Israel Guttierez; Boehm A Kristi; Thomas E Hutson; William Berry; Lina Asmar; Daniel Von Hoff
Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy.
Clinical genitourinary cancer 2007;5(7):457-9.
2007: Tomislav Dragovich; Mark Huberman; Daniel Von Hoff; Eric K Rowinsky; Paul Nadler; Debra Wood; Marta Hamilton; George Hage; Julie Wolf; Amita Patnaik
Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.
Cancer chemotherapy and pharmacology 2007;60(2):295-303.
2007: Ming Zhu; Vijay Gokhale; Lajos Szabo; Ruben M Munoz; Hyounggee Baek; Sridevi Bashyam; Laurence H Hurley; Daniel Von Hoff; Haiyong Han
Identification of a novel inhibitor of urokinase-type plasminogen activator.
Molecular cancer therapeutics 2007;6(4):1348-56.
2007: Daruka Mahadevan; Daniel Von Hoff
Tumor-stroma interactions in pancreatic ductal adenocarcinoma.
Molecular cancer therapeutics 2007;6(4):1186-97.
2006: Tomislav Dragovich; David S Mendelson; Sandra Kurtin; Kelly Richardson; Daniel Von Hoff; Axel Hoos
A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer.
Cancer chemotherapy and pharmacology 2006;58(6):759-64.
2006: Philip L Lorenzi; William C Reinhold; Martina Rudelius; Michele Gunsior; Uma Shankavaram; Kimberly J Bussey; Uwe Scherf; Gabriel S Eichler; Scott E Martin; Koei Chin; Joe Gray; Elise C Kohn; Ivan D Horak; Daniel Von Hoff; Mark Raffeld; Paul Goldsmith; Natasha J Caplen; John N Weinstein
Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells.
Molecular cancer therapeutics 2006;5(11):2613-23.
2006: Steven L Warner; Ruben M Munoz; Phillip Stafford; Erich Koller; Laurence H Hurley; Daniel Von Hoff; Haiyong Han
Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells.
Molecular cancer therapeutics 2006;5(10):2450-8.
2006: Hong Wang; Haiyong Han; Daniel Von Hoff
Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells.
Cancer research 2006;66(19):9722-30.
2006: Linda L Garland; Charles Taylor; Deborah L Pilkington; Jan L Cohen; Daniel Von Hoff
A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(17):5182-9.
2006: Haiyong Han; Daniel Von Hoff
Aurora sheds light on head and neck squamous cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(17):5003-4.
2006: Hong Wang; Haiyong Han; Spyro Mousses; Daniel Von Hoff
Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents.
Seminars in oncology 2006;33(4):513-20.
2006: Laurence H Hurley; Daniel Von Hoff; Adam Siddiqui-Jain; Danzhou Yang
Drug targeting of the c-MYC promoter to repress gene expression via a G-quadruplex silencer element.
Seminars in oncology 2006;33(4):498-512.
2006: Steven L Warner; Phillip J Gray; Daniel Von Hoff
Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others.
Seminars in oncology 2006;33(4):436-48.
2006: Steven L Warner; Sridevi Bashyam; Hariprasad Vankayalapati; David J Bearss; Haiyong Han; Daruka Mahadevan; Daniel Von Hoff; Laurence H Hurley
Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach.
Molecular cancer therapeutics 2006;5(7):1764-73.
2006: Anthony W Tolcher; Desiree Hao; Johann S de Bono; Alex Miller; Amita Patnaik; Lisa A Hammond; Leslie Ann Smetzer; Jill van Wart Hood; James Merritt; Eric K Rowinsky; Chris H Takimoto; Daniel Von Hoff; S Gail Eckhardt
Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(13):2052-8.
2006: Daniel Von Hoff
What's new in pancreatic cancer treatment pipeline?
Best practice & research. Clinical gastroenterology 2006;20(2):315-26.
2005: Bret J Stephens; Haiyong Han; Vijay Gokhale; Daniel Von Hoff
PRL phosphatases as potential molecular targets in cancer.
Molecular cancer therapeutics 2005;4(11):1653-61.
2005: David W Nyman; Kimberley J Campbell; Evan M Hersh; Kristen Long; Kelly Richardson; Vuong Trieu; Neil Desai; Michael J Hawkins; Daniel Von Hoff
Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(31):7785-93.
2005: Helmut Oettle; D Richards; Ramesh K Ramanathan; J L van Laethem; M Peeters; M Fuchs; A Zimmermann; W John; Daniel Von Hoff; M Arning; H L Kindler
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(10):1639-45.
2005: Linda L Garland; Barbara J Gitlitz; Scot W Ebbinghaus; Henry Pan; Hans de Haan; Raj K Puri; Daniel Von Hoff; Robert Figlin
Phase I trial of intravenous IL-4 pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2005;28(4):376-81.
2005: Ephraim Philip Lansky; Daniel Von Hoff
Complex and simple.
Leukemia research 2005;29(6):601-2.
2005: Joyce A O'Shaughnessy; Svetislava Vukelja; Frankie A Holmes; Michael Savin; Monte Jones; Donald Royall; Martine George; Daniel Von Hoff
Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy.
Clinical breast cancer 2005;5(6):439-46.
2004: Govindarajan Manikumar; Randy M Wadkins; David J Bearss; Daniel Von Hoff; Mansukh C Wani; Monroe E Wall
Camptothecin analogs with bulky, hydrophobic substituents at the 7-position via a Grignard reaction.
Bioorganic & medicinal chemistry letters 2004;14(21):5377-81.
2004: Randy M Wadkins; David J Bearss; Govindarajan Manikumar; Mansukh C Wani; Monroe E Wall; Daniel Von Hoff
Hydrophilic camptothecin analogs that form extremely stable cleavable complexes with DNA and topoisomerase I.
Cancer research 2004;64(18):6679-83.
2004: Deborah Schrag; Harinder S Garewal; Harold J Burstein; David J Samson; Daniel Von Hoff; Mark R Somerfield
American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(17):3631-8.
2004: Randy M Wadkins; David J Bearss; Govindarajan Manikumar; Mansukh C Wani; Monroe E Wall; Daniel Von Hoff
Topoisomerase I-DNA complex stability induced by camptothecins and its role in drug activity.
Current medicinal chemistry. Anti-cancer agents 2004;4(4):327-34.
2004: Phillip J Gray; David J Bearss; Haiyong Han; Raymond B Nagle; Ming Tsao; Nicholas Dean; Daniel Von Hoff
Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer.
Molecular cancer therapeutics 2004;3(5):641-6.
2004: Eric Van Cutsem; H van de Velde; P Karasek; Helmut Oettle; W L Vervenne; A Szawlowski; Patrick Schoffski; S Post; Chris Verslype; H Neumann; H Safran; Yves Humblet; Juan Jose Perez-Ruixo; Y Ma; Daniel Von Hoff
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(8):1430-8.
2004: Sangeeta Rojanala; Haiyong Han; Rubén M Muñoz; Walden Browne; Raymond B Nagle; Daniel Von Hoff; David J Bearss
The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer.
Molecular cancer therapeutics 2004;3(4):451-7.
2004: Lisa A Hammond; John R Eckardt; John Kuhn; Stanton L Gerson; Tom Johnson; Lon Smith; Ronald L Drengler; Elizabeth Campbell; Geoffrey R Weiss; Daniel Von Hoff; Eric K Rowinsky
A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(5):1645-56.
2003: Bahram Forouzesh; Chris H Takimoto; Andrew Goetz; Sami Diab; Lisa A Hammond; Leslie Ann Smetzer; Garry Schwartz; Robert Gazak; John T Callaghan; Daniel Von Hoff; Eric K Rowinsky
A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(15):5540-9.
2003: Steven L Warner; David J Bearss; Haiyong Han; Daniel Von Hoff
Targeting Aurora-2 kinase in cancer.
Molecular cancer therapeutics 2003;2(6):589-95.
2003: Garry H Schwartz; Amita Patnaik; Lisa A Hammond; Jinee Rizzo; K Berg; Daniel Von Hoff; Eric K Rowinsky
A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(5):775-82.
2003: Hariprasad Vankayalapati; David J Bearss; José W Saldanha; Rubén M Muñoz; Sangeeta Rojanala; Daniel Von Hoff; Daruka Mahadevan
Targeting aurora2 kinase in oncogenesis: a structural bioinformatics approach to target validation and rational drug design.
Molecular cancer therapeutics 2003;2(3):283-94.
2003: David Nishioka; Vanessa Marcell; Meghan Cunningham; Merium Khan; Daniel Von Hoff; Elzbieta Izbicka
The use of early sea urchin embryos in anticancer drug testing.
Methods in molecular medicine 2003;85():265-76.
2002: Daniel Von Hoff
Translational research: stop, look, listen--if you expect to grow up tall.
Cancer biology & therapy 2002;1(6):718-20.
2002: Daniel Von Hoff; David J Bearss
New drugs for patients with pancreatic cancer.
Current opinion in oncology 2002;14(6):621-7.
2002: Desirée Hao; Jinee D Rizzo; Stephanie Stringer; Rodney V Moore; Jennifer Marty; Daniel L Dexter; Gina L Mangold; Jim B Camden; Daniel Von Hoff; Steven D Weitman
Preclinical antitumor activity and pharmacokinetics of methyl-2-benzimidazolecarbamate (FB642).
Investigational new drugs 2002;20(3):261-70.
2002: Lillian L Siu; Eric K Rowinsky; Lisa A Hammond; Geoffrey R Weiss; Manuel Hidalgo; Gary M Clark; Judy Moczygemba; Les Choi; Ron Linnartz; Nicholas C Barbet; Ivo Sklenar; Renaud Capdeville; Gregory Gan; Carl W Porter; Daniel Von Hoff; S Gail Eckhardt
A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2157-66.
2002: Cory L Grand; Haiyong Han; Rubén M Muñoz; Steven D Weitman; Daniel Von Hoff; Laurence H Hurley; David J Bearss
The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo.
Molecular cancer therapeutics 2002;1(8):565-73.
2002: Haiyong Han; David J Bearss; L Walden Browne; Robert Calaluce; Raymond B Nagle; Daniel Von Hoff
Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray.
Cancer research 2002;62(10):2890-6.
2002: Weixin Wang; Stephen J Waters; John R MacDonald; Caleb Roth; Shujun Shentu; James W Freeman; Daniel Von Hoff; Alexander R Miller
Irofulven (6-hydroxymethylacylfulvene, MGI 114)-induced apoptosis in human pancreatic cancer cells is mediated by ERK and JNK kinases.
Anticancer research 2002;22(2A):559-64.
2002: Joyce A O'Shaughnessy; Gary J Kelloff; Gary B Gordon; Andrew J Dannenberg; Waun Ki Hong; Carol J Fabian; Caroline C Sigman; Monica M Bertagnolli; Steven P Stratton; Stephen Lam; William G Nelson; Frank L Meyskens; David S Alberts; Michele Follen; Anil K Rustgi; Vassiliki A Papadimitrakopoulou; Peter T Scardino; Adi F Gazdar; Lee W Wattenberg; Michael B. Sporn; Wael A Sakr; Scott M Lippman; Daniel Von Hoff
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(2):314-46.
2002: T Petit; KK Davidson; Cesario Cerna; RA Lawrence; Daniel Von Hoff; C Heise; D Kirn; Elzbieta Izbicka
Efficient induction of apoptosis by ONYX-015 adenovirus in human colon cancer cell lines regardless of p53 status.
Anti-cancer drugs 2002;13(1):47-50.
2002: Miguel A Villalona-Calero; S Gail Eckhardt; Geoffrey Weiss; Manuel Hidalgo; Jos H Beijnen; Charlotte van Kesteren; Hilde Rosing; Elizabeth Campbell; Maura Kraynak; Luis Lopez-Lazaro; Cecilia Guzman; Daniel Von Hoff; José Jimeno; Eric K Rowinsky
A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(1):75-85.
2001: W Duan; Anupama Rangan; Hariprasad Vankayalapati; Mu-Yong Kim; Q Zeng; Daekyu Sun; Haiyong Han; OY Fedoroff; David Nishioka; S Y Rha; Elzbieta Izbicka; Daniel Von Hoff; Laurence H Hurley
Design and synthesis of fluoroquinophenoxazines that interact with human telomeric G-quadruplexes and their biological effects.
Molecular cancer therapeutics 2001;1(2):103-20.
2001: Mace L Rothenberg; John Kuhn; L J Schaaf; Gladys I Rodriguez; S Gail Eckhardt; Miguel A Villalona-Calero; David A Rinaldi; Lisa A Hammond; S Hodges; A Sharma; Gary L Elfring; R G Petit; Paula K Locker; Langdon L Miller; Daniel Von Hoff
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(11):1631-41.
2001: Garry Schwartz; T R Johnson; Andrew Goetz; Howard A Burris; Leslie Ann Smetzer; T Lampkin; J Sailstad; JA Hohneker; Daniel Von Hoff; Eric K Rowinsky
A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(7):1901-11.
2001: Manuel Hidalgo; Lillian L Siu; J Nemunaitis; Jinee Rizzo; Lisa A Hammond; Chris H Takimoto; S Gail Eckhardt; Anthony W Tolcher; Carolyn D Britten; Louis Denis; K Ferrante; Daniel Von Hoff; S Silberman; Eric K Rowinsky
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(13):3267-79.
2001: Weixin Wang; Stephen J Waters; John R MacDonald; Daniel Von Hoff; William E Strodel; Alexander R Miller
Irofulven (6-hydroxymethylacylfulvene, MGI 114) induces caspase 8 and 9-mediated apoptosis in human pancreatic adenocarcinoma cells.
Anticancer research 2001;21(3B):1789-94.
2001: Miguel A Villalona-Calero; JL Blum; Stephen E Jones; Sami Diab; Richard M Elledge; P Khoury; Daniel Von Hoff; Maura Kraynak; Judy Moczygemba; P Kromelis; T Griffin; Eric K Rowinsky
A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(5):605-14.
2001: Lisa A Hammond; K Davidson; R Lawrence; Jim B Camden; Daniel Von Hoff; Steven D Weitman; Elzbieta Izbicka
Exploring the mechanisms of action of FB642 at the cellular level.
Journal of cancer research and clinical oncology 2001;127(5):301-13.
2001: E Raymond; S Faivre; G Weiss; J McGill; K Davidson; E Izbicka; John Kuhn; C Allred; G M Clark; Daniel Von Hoff
Effects of hydroxyurea on extrachromosomal DNA in patients with advanced ovarian carcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(5):1171-80.
2001: Jon I Williams; Steven D Weitman; C M Gonzalez; C H Jundt; J Marty; S D Stringer; Kenneth J Holroyd; McLane Michael; Qiming Chen; Michael Zasloff; Daniel Von Hoff
Squalamine treatment of human tumors in nu/nu mice enhances platinum-based chemotherapies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(3):724-33.
2001: T Petit; KK Davidson; RA Lawrence; Daniel Von Hoff; Elzbieta Izbicka
Neuropeptide receptor status in human tumor cell lines.
Anti-cancer drugs 2001;12(2):133-6.
2001: Miguel A Villalona-Calero; Joseph P Eder; D L Toppmeyer; L F Allen; Robert J Fram; R Velagapudi; M Myers; A Amato; K Kagen-Hallet; B Razvillas; Donald Kufe; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(3):857-69.
2000: David J Bearss; Laurence H Hurley; Daniel Von Hoff
Telomere maintenance mechanisms as a target for drug development.
Oncogene 2000;19(56):6632-41.
2000: S Gail Eckhardt; Sharyn D Baker; Carolyn D Britten; Manuel Hidalgo; Lillian Siu; Lisa A Hammond; Miguel A Villalona-Calero; Sally A Felton; Ronald L Drengler; John Kuhn; Gary M Clark; S L Smith; John R MacDonald; C Smith; Judy Moczygemba; Steven D Weitman; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(24):4086-97.
2000: Amita Patnaik; Eric K Rowinsky; B K Tammara; Manuel Hidalgo; Ronald L Drengler; A M Garner; Lillian L Siu; Lisa A Hammond; Sally A Felton; S Mallikaarjun; Daniel Von Hoff; S Gail Eckhardt
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(23):3974-85.
2000: Lisa A Hammond; Susan G Hilsenbeck; S Gail Eckhardt; Jennifer Marty; Gina L Mangold; John R MacDonald; Eric K Rowinsky; Daniel Von Hoff; Steven D Weitman
Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model.
European journal of cancer (Oxford, England : 1990) 2000;36(18):2430-6.
2000: Eric K Rowinsky; T R Johnson; Charles E Geyer; Lisa A Hammond; S Gail Eckhardt; Ronald L Drengler; Leslie Ann Smetzer; John Coyle; Jinee Rizzo; Garry Schwartz; Anthony W Tolcher; Daniel Von Hoff; Robert L De Jager
DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(17):3151-63.
2000: Steven D Weitman; H Barrera; R Moore; C Gonzalez; Jennifer Marty; Susan G Hilsenbeck; John R MacDonald; Stephen J Waters; Daniel Von Hoff
MGI 114: augmentation of antitumor activity when combined with topotecan.
Journal of pediatric hematology/oncology 2000;22(4):306-14.
2000: H Soda; E Raymond; S Sharma; R Lawrence; K Davidson; M Oka; S Kohno; E Izbicka; Daniel Von Hoff
Effects of androgens on telomerase activity in normal and malignant prostate cells in vitro.
The Prostate 2000;43(3):161-8.
2000: Eric Raymond; J C Soria; Elzbieta Izbicka; F Boussin; Laurence H Hurley; Daniel Von Hoff
DNA G-quadruplexes, telomere-specific proteins and telomere-associated enzymes as potential targets for new anticancer drugs.
Investigational new drugs 2000;18(2):123-37.
2000: Steven D Weitman; J Marty; J Jolivet; C Locas; Daniel Von Hoff
The new dioxolane, (-)-2'-deoxy-3'-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1574-8.
2000: Anthony W Tolcher; Cheryl Aylesworth; Jinee Rizzo; Elzbieta Izbicka; Elizabeth Campbell; John Kuhn; Geoffrey Weiss; Daniel Von Hoff; Eric K Rowinsky
A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(3):333-8.
2000: S Y Rha; Elzbieta Izbicka; R Lawrence; K Davidson; D Sun; Mary Pat Moyer; David G Roodman; Laurence H Hurley; Daniel Von Hoff
Effect of telomere and telomerase interactive agents on human tumor and normal cell lines.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(3):987-93.
2000: Ian Ganly; David H Kirn; G Eckhardt; Gladys I Rodriguez; David S Soutar; Randal Otto; Andrew Robertson; O Park; M L Gulley; Carla Heise; Daniel Von Hoff; Stanley B Kaye; S G Eckhardt
A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(3):798-806.
2000: Laurence H Hurley; RT Wheelhouse; Daekyu Sun; Sean M Kerwin; Miguel Salazar; OY Fedoroff; F X Han; Haiyong Han; Elzbieta Izbicka; Daniel Von Hoff
G-quadruplexes as targets for drug design.
Pharmacology & therapeutics 2000;85(3):141-58.
2000: B Vladu; Jan Woynarowski; Govindarajan Manikumar; Mansukh C Wani; Monroe E Wall; Daniel Von Hoff; Randy M Wadkins
7- and 10-substituted camptothecins: dependence of topoisomerase I-DNA cleavable complex formation and stability on the 7- and 10-substituents.
Molecular pharmacology 2000;57(2):243-51.
2000: Carolyn D Britten; Eric K Rowinsky; Sharyn D Baker; Geoffrey R Weiss; Lon Smith; Joseph Stephenson; M Rothenberg; Leslie Ann Smetzer; J Cramer; W Collins; Daniel Von Hoff; S Gail Eckhardt
A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(1):42-9.
2000: Wayne L Monsky; D K Heddens; G M Clark; Daniel Von Hoff; C A Coltman; R T Dorr; D S Alberts
Comparison of young clinical investigators' accuracy and reproducibility when measuring pulmonary and skin surface nodules using a circumferential measurement versus a standard caliper measurement: American Association for Cancer Research/American Society of Clinical Oncology Clinical Trials Workshop.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(2):437-44.
2000: Eric K Rowinsky; R Humphrey; Lisa A Hammond; Cheryl Aylesworth; Leslie Ann Smetzer; Manuel Hidalgo; M Morrow; Lon Smith; A Garner; J M Sorensen; Daniel Von Hoff; S Gail Eckhardt
Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(1):178-86.
2000: Manuel Hidalgo; Miguel A Villalona-Calero; S Gail Eckhardt; Ronald L Drengler; G Rodriguez; Lisa A Hammond; Sami Diab; Geoffrey Weiss; A M Garner; Elizabeth Campbell; K Davidson; A Louie; J D O'Neil; R von Borstel; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(1):167-77.
1999: Maurizio Del Poeta; S F Chen; Daniel Von Hoff; Christine C Dykstra; Mansukh C Wani; Govindarajan Manikumar; Joseph Heitman; Monroe E Wall; John R Perfect
Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells.
Antimicrobial agents and chemotherapy 1999;43(12):2862-8.
1999: Miguel A Villalona-Calero; T Petit; John Kuhn; P Cobb; Maura Kraynak; S Gail Eckhardt; Ronald L Drengler; Cecilia Simmons; P Santabarbara; Daniel Von Hoff; Eric K Rowinsky
A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(11):3369-78.
1999: Eric K Rowinsky; J J Windle; Daniel Von Hoff
Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(11):3631-52.
1999: John Nemunaitis; Jon T Holmlund; Maura Kraynak; D Richards; J Bruce; N Ognoskie; T Jesse Kwoh; Richard S Geary; Andrew Dorr; Daniel Von Hoff; S Gail Eckhardt
Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(11):3586-95.
1999: Paula M Fracasso; Benjamin R Tan; M Grieff; J Stephenson; H Liapis; N L Umbeck; Daniel Von Hoff; eric rowinsky
Membranoproliferative glomerulonephritis following gemcitabine and vinorelbine chemotherapy for peritoneal mesothelioma.
Journal of the National Cancer Institute 1999;91(20):1779-80.
1999: Manuel Hidalgo; Elzbieta Izbicka; S Gail Eckhardt; J R MacDonald; Cesario Cerna; Lionel Gomez; Eric K Rowinsky; Steven D Weitman; Daniel Von Hoff
Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units.
Anti-cancer drugs 1999;10(9):837-44.
1999: Martee Hensley; Lynn Schuchter; Celeste Lindley; N J Meropol; GARY COHEN; G Broder; W J Gradishar; D M Green; R J Langdon; R B Mitchell; R Negrin; Ted P Szatrowski; J T Thigpen; Daniel Von Hoff; T H Wasserman; Eric P Winer; David G Pfister
American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(10):3333-55.
1999: Elzbieta Izbicka; David Nishioka; V Marcell; E Raymond; KK Davidson; RA Lawrence; RT Wheelhouse; Laurence H Hurley; R S Wu; Daniel Von Hoff
Telomere-interactive agents affect proliferation rates and induce chromosomal destabilization in sea urchin embryos.
Anti-cancer drug design 1999;14(4):355-65.
1999: Lisa A Hammond; John R Eckardt; Sharyn D Baker; S Gail Eckhardt; Margaret Dugan; K Forral; P Reidenberg; Paul Statkevich; Geoffrey R Weiss; David A Rinaldi; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(8):2604-13.
1999: RA Lawrence; Elzbieta Izbicka; R L De Jager; A Tohgo; G M Clark; Steven D Weitman; eric rowinsky; Daniel Von Hoff
Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells.
Anti-cancer drugs 1999;10(7):655-61.
1999: Randy M Wadkins; Philip Potter; B Vladu; Jennifer Marty; Gina L Mangold; Steven D Weitman; Govindarajan Manikumar; Mansukh C Wani; Monroe E Wall; Daniel Von Hoff
Water soluble 20(S)-glycinate esters of 10,11-methylenedioxycamptothecins are highly active against human breast cancer xenografts.
Cancer research 1999;59(14):3424-8.
1999: Carolyn D Britten; Eric K Rowinsky; Sharyn D Baker; S S Agarwala; John R Eckardt; RE Barrington; Sami Diab; Lisa A Hammond; T Johnson; Miguel A Villalona-Calero; U Fraass; Paul Statkevich; Daniel Von Hoff; S Gail Eckhardt
A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(7):1629-37.
1999: E Raymond; Daekyu Sun; Elzbieta Izbicka; Gina L Mangold; E Silvas; BE Windle; S Sharma; H Soda; R Laurence; K Davidson; Daniel Von Hoff
A human breast cancer model for the study of telomerase inhibitors based on a new biotinylated-primer extension assay.
British journal of cancer 1999;80(9):1332-41.
1999: T Petit; K Davidson; Elzbieta Izbicka; Daniel Von Hoff
Elimination of extrachromosomal c-myc genes by hydroxyurea induces apoptosis.
Apoptosis : an international journal on programmed cell death 1999;4(3):163-7.
1999: Miguel A Villalona-Calero; Geoffrey R Weiss; Howard A Burris; Maura Kraynak; G Rodrigues; Ronald L Drengler; S Gail Eckhardt; Bruno Reigner; Judy Moczygemba; Hans-Ulrich Burger; T Griffin; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(6):1915-25.
1999: S Gail Eckhardt; Jinee Rizzo; K R Sweeney; Gillian F Cropp; Sharyn D Baker; Maura Kraynak; John Kuhn; Miguel A Villalona-Calero; L Hammond; Geoffrey Weiss; A Thurman; Lon Smith; Ronald L Drengler; John R Eckardt; Judy Moczygemba; Alison L Hannah; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(4):1095-104.
1999: Manuel Hidalgo; David A Rinaldi; G Medina; T Griffin; J Turner; Daniel Von Hoff
A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia.
Anti-cancer drugs 1999;10(4):393-5.
1999: T Petit; Elzbieta Izbicka; RA Lawrence; W R Bishop; Steven D Weitman; Daniel Von Hoff
Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(4):449-53.
1999: Daekyu Sun; C C Lopez-Guajardo; J Quada; Laurence H Hurley; Daniel Von Hoff
Regulation of catalytic activity and processivity of human telomerase.
Biochemistry 1999;38(13):4037-44.
1999: S G Hilsenbeck; Daniel Von Hoff
Measure once or twice -- does it really matter?
Journal of the National Cancer Institute 1999;91(6):494-5.
1999: Elzbieta Izbicka; K Davidson; R Lawrence; Richard J Cote; John R MacDonald; Daniel Von Hoff
Cytotoxic effects of MGI 114 are independent of tumor p53 or p21 expression.
Anticancer research 1999;19(2A):1299-307.
1999: Elzbieta Izbicka; KK Davidson; RA Lawrence; John R MacDonald; Daniel Von Hoff
5,6-Dihydro-5'-azacytidine (DHAC) affects estrogen sensitivity in estrogen-refractory human breast carcinoma cell lines.
Anticancer research 1999;19(2A):1293-8.
1999: Elzbieta Izbicka; John R MacDonald; K Davidson; RA Lawrence; L Gomez; Daniel Von Hoff
5,6 Dihydro-5'-azacytidine (DHAC) restores androgen responsiveness in androgen-insensitive prostate cancer cells.
Anticancer research 1999;19(2A):1285-91.
1999: T Petit; Elzbieta Izbicka; RA Lawrence; C Nalin; Steven D Weitman; Daniel Von Hoff
Activity of MKT 077, a rhodacyanine dye, against human tumor colony-forming units.
Anti-cancer drugs 1999;10(3):309-15.
1999: Sami Diab; Susan G Hilsenbeck; Elzbieta Izbicka; Steven D Weitman; Daniel Von Hoff
Significant activity of a novel cytotoxic agent, LY295501, against a wide range of tumors in the human tumor cloning system.
Anti-cancer drugs 1999;10(3):303-7.
1999: Manuel Hidalgo; Elzbieta Izbicka; Cesario Cerna; Lionel Gomez; Eric K Rowinsky; Steven D Weitman; Daniel Von Hoff
Comparative activity of the cyclopropylpyrroloindole compounds adozelesin, bizelesin and carzelesin in a human tumor colony-forming assay.
Anti-cancer drugs 1999;10(3):295-302.
1999: Carolyn D Britten; Susan G Hilsenbeck; S Gail Eckhardt; Jennifer Marty; Gina L Mangold; John R MacDonald; Eric K Rowinsky; Daniel Von Hoff; Steven D Weitman
Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.
Cancer research 1999;59(5):1049-53.
1999: Mace L Rothenberg; J V Cox; Russell F DeVore; J D Hainsworth; R Pazdur; S E Rivkin; J S Macdonald; C E Geyer; J Sandbach; D L Wolf; J S Mohrland; Gary L Elfring; Langdon L Miller; Daniel Von Hoff
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
Cancer 1999;85(4):786-95.
1999: T Petit; Cheryl Aylesworth; Howard A Burris; Peter M Ravdin; G Rodriguez; Lon Smith; N Peacock; Leslie Ann Smetzer; R Bellet; Daniel Von Hoff; Eric K Rowinsky
A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(2):223-9.
1999: Ronald L Drengler; John Kuhn; Larry J Schaaf; Gladys I Rodriguez; Miguel A Villalona-Calero; Lisa A Hammond; J A Stephenson; S Hodges; Maura Kraynak; B A Staton; Gary L Elfring; Paula K Locker; Langdon L Miller; Daniel Von Hoff; Mace L Rothenberg
Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(2):685-96.
1999: Sami Diab; Sharyn D Baker; A Joshi; Howard A Burris; P W Cobb; Miguel A Villalona-Calero; S Gail Eckhardt; Geoffrey R Weiss; Gladys I Rodriguez; Ronald L Drengler; Maura Kraynak; L Hammond; M Finizio; Daniel Von Hoff; Eric K Rowinsky
A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(2):299-308.
1999: Elzbieta Izbicka; RT Wheelhouse; E Raymond; KK Davidson; RA Lawrence; Daekyu Sun; BE Windle; Laurence H Hurley; Daniel Von Hoff
Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells.
Cancer research 1999;59(3):639-44.
1999: David A Rinaldi; John Kuhn; Howard A Burris; F A Dorr; G Rodriguez; S Gail Eckhardt; Stephen E Jones; J R Woodworth; S Baker; C Langley; D Mascorro; T Abrahams; Daniel Von Hoff
A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.
Cancer chemotherapy and pharmacology 1999;44(5):372-80.
1999: Carolyn D Britten; Elzbieta Izbicka; Susan G Hilsenbeck; R Lawrence; K Davidson; Cesario Cerna; Lionel Gomez; Eric K Rowinsky; Steven D Weitman; Daniel Von Hoff
Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay.
Cancer chemotherapy and pharmacology 1999;44(2):105-10.
1999: H Soda; Eric Raymond; S Sharma; R Lawrence; Cesario Cerna; Lionel Gomez; R Schaub; Daniel Von Hoff; Elzbieta Izbicka
Recombinant human interleukin-11 is unlikely to stimulate the growth of the most common solid tumors.
Anti-cancer drugs 1999;10(1):97-101.
1999: D Genre; P Viens; Daniel Von Hoff; G M Clark
Patients who are receiving concomitant medications should not systematically be excluded from phase I studies.
Anti-cancer drugs 1999;10(1):1-7.
1999: Steven D Weitman; Gina L Mangold; Jennifer Marty; D Dexter; Susan G Hilsenbeck; J Rake; P Juniewicz; Daniel Von Hoff
Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft.
Cancer chemotherapy and pharmacology 1999;43(5):402-8.
1999: C J H Gerrits; J H M Schellens; Howard A Burris; John R Eckardt; A S T Planting; M E L van der Burg; Gladys I Rodriguez; Walter J Loos; V van Beurden; IR Hudson; Daniel Von Hoff; Jaap Verweij
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(1):69-75.
1998: D Sun; Laurence H Hurley; Daniel Von Hoff
Telomerase assay using biotinylated-primer extension and magnetic separation of the products.
BioTechniques 1998;25(6):1046-51.
1998: Manuel Hidalgo; G Rodriguez; John Kuhn; T Brown; Geoffrey Weiss; J P MacGovren; Daniel Von Hoff; Eric K Rowinsky
A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(11):2763-70.
1998: Daniel Von Hoff
Promising new agents for treatment of patients with colorectal cancer.
Seminars in oncology 1998;25(5 Suppl 11):47-52.
1998: Vicente Valero; Stephen E Jones; Daniel Von Hoff; Daniel J Booser; Robert G Mennel; Peter M Ravdin; Frankie A Holmes; Zia Rahman; M W Schottstaedt; J K Erban; Laura Guerra; R H Earhart; Gabriel N Hortobagyi; Howard A Burris
A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(10):3362-8.
1998: E Izbicka; R Lawrence; E Raymond; G Eckhardt; Glynn Faircloth; J Jimeno; G Clark; Daniel Von Hoff
In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(9):981-7.
1998: Eric K Rowinsky; Lon Smith; Y M Wang; P Chaturvedi; M Villalona; Elizabeth Campbell; Cheryl Aylesworth; S Gail Eckhardt; L Hammond; Maura Kraynak; Ronald L Drengler; Joseph Stephenson; M W Harding; Daniel Von Hoff
Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(9):2964-76.
1998: Lillian L Siu; G Attardo; Elzbieta Izbicka; R Lawrence; Cesario Cerna; Lionel Gomez; K Davidson; C Finkle; C Marsolais; Eric K Rowinsky; Daniel Von Hoff
Activity of (-)-2'-deoxy-3'-oxacytidine (BCH-4556) against human tumor colony-forming units.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(8):885-91.
1998: K Davidson; T Petit; Elzbieta Izbicka; SK Koester; Daniel Von Hoff
Mitoguazone induces apoptosis via a p53-independent mechanism.
Anti-cancer drugs 1998;9(7):635-40.
1998: Daniel Von Hoff
Phase I trials of dexrazoxane and other potential applications for the agent.
Seminars in oncology 1998;25(4 Suppl 10):31-6.
1998: Mace L Rothenberg; John Kuhn; Larry J Schaaf; Ronald L Drengler; S Gail Eckhardt; Miguel A Villalona-Calero; L Hammond; Langdon L Miller; R G Petit; Eric K Rowinsky; Daniel Von Hoff
Alternative dosing schedules for irinotecan.
Oncology (Williston Park, N.Y.) 1998;12(8 Suppl 6):68-71.
1998: Miguel A Villalona-Calero; Sharyn D Baker; L Hammond; Cheryl Aylesworth; S Gail Eckhardt; Maura Kraynak; Robert J Fram; Steven Fischkoff; R Velagapudi; D Toppmeyer; B Razvillas; K Jakimowicz; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(8):2770-9.
1998: S Sharma; E Raymond; H Soda; Elzbieta Izbicka; K Davidson; R Lawrence; Daniel Von Hoff
Dimethyl sulfoxide (DMSO) causes a reversible inhibition of telomerase activity in a Burkitt lymphoma cell line.
Leukemia research 1998;22(8):663-70.
1998: Mace L Rothenberg; A Sharma; Geoffrey R Weiss; Miguel A Villalona-Calero; John R Eckardt; Cheryl Aylesworth; Maura Kraynak; David A Rinaldi; Gladys I Rodriguez; Howard A Burris; S Gail Eckhardt; CD Stephens; K Forral; S J Nicol; Daniel Von Hoff
Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(7):733-8.
1998: A S Morgan; P E Sanderson; R F Borch; Kenneth D Tew; Y Niitsu; T Takayama; Daniel Von Hoff; Elzbieta Izbicka; Gina L Mangold; C Paul; U Broberg; B Mannervik; W D Henner; LM Kauvar
Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase.
Cancer research 1998;58(12):2568-75.
1998: C J H Gerrits; Howard A Burris; J H M Schellens; A S T Planting; M E van den Burg; Gladys I Rodriguez; V van Beurden; Walter J Loos; IR Hudson; S Fields; Jaap Verweij; Daniel Von Hoff
Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.
European journal of cancer (Oxford, England : 1990) 1998;34(7):1030-5.
1998: Lisa A Hammond; John R Eckardt; R Ganapathi; Howard A Burris; G A Rodriguez; S Gail Eckhardt; Mace L Rothenberg; Geoffrey R Weiss; John Kuhn; S Hodges; Daniel Von Hoff; Eric K Rowinsky
A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(6):1459-67.
1998: C J H Gerrits; Howard A Burris; J H M Schellens; John R Eckardt; A S T Planting; M E L van der Burg; Gladys I Rodriguez; Walter J Loos; V van Beurden; IR Hudson; S Fields; Daniel Von Hoff; Jaap Verweij
Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(5):1153-8.
1998: Daniel Von Hoff
There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(5):1079-86.
1998: H Soda; Eric Raymond; S Sharma; R Lawrence; Cesario Cerna; Lionel Gomez; G A Timony; Daniel Von Hoff; Elzbieta Izbicka
Antiproliferative effects of recombinant human bone morphogenetic protein-2 on human tumor colony-forming units.
Anti-cancer drugs 1998;9(4):327-31.
1998: Eric Raymond; R Lawrence; Elzbieta Izbicka; Sandrine Faivre; Daniel Von Hoff
Activity of oxaliplatin against human tumor colony-forming units.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(4):1021-9.
1998: Richard L Schilsky; JA Hohneker; Mark J Ratain; Linda Janisch; Leslie Ann Smetzer; V S Lucas; SP Khor; R Diasio; Daniel Von Hoff; Howard A Burris
Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(4):1450-7.
1998: Steven D Weitman; R Moore; H Barrera; Nai-Kong V Cheung; Elzbieta Izbicka; Daniel Von Hoff
In vitro antitumor activity of rebeccamycin analog (NSC# 655649) against pediatric solid tumors.
Journal of pediatric hematology/oncology 1998;20(2):136-9.
1998: S Gail Eckhardt; Sharyn D Baker; John R Eckardt; Thomas G Burke; D L Warner; John Kuhn; G Rodriguez; S Fields; A Thurman; Lon Smith; Mace L Rothenberg; L White; Paul Wissel; R Kunka; S DePee; D Littlefield; Howard A Burris; Daniel Von Hoff; Eric K Rowinsky
Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(3):595-604.
1998: Gladys I Rodriguez; John Kuhn; Geoffrey R Weiss; Susan G Hilsenbeck; John R Eckardt; A Thurman; David A Rinaldi; S Hodges; Daniel Von Hoff; Eric K Rowinsky
A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea.
Blood 1998;91(5):1533-41.
1998: E Izbicka; W S Dalton; Dean A Troyer; Daniel Von Hoff
Expression of two multidrug resistance genes in human prostatic carcinomas.
Journal of the National Cancer Institute 1998;90(2):166-7.
1998: Elzbieta Izbicka; R Lawrence; K Davidson; J B Rake; Daniel Von Hoff
Effects of SW 33377, SW 68210 and SW 71425 thioxanthones on in vitro colony formation of freshly explanted human tumor cells.
Investigational new drugs 1998;16(3):221-5.
1998: Lillian L Siu; Daniel Von Hoff; A Rephaeli; Elzbieta Izbicka; Cesario Cerna; Lionel Gomez; Eric K Rowinsky; S Gail Eckhardt
Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units.
Investigational new drugs 1998;16(2):113-9.
1998: Gladys I Rodriguez; John Kuhn; Geoffrey Weiss; P De La Cruz; Pamela New; S M Fields; John R Eckardt; L Campbell; G M Clark; Susan G Hilsenbeck; Daniel Von Hoff
A phase I and pharmacokinetic trial of terephthalamidine (NSC 57155) as a 120-hour continuous infusion.
Investigational new drugs 1998;16(1):57-67.
1998: N W Peacock; Howard A Burris; V Dieras; L Smith; Gladys I Rodriguez; John R Eckardt; Suzanne F Jones; J Hardy; JA Hohneker; J Bigley; Daniel Von Hoff
A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors.
Investigational new drugs 1998;16(1):37-43.
1998: Howard A Burris; E Raymond; A Awada; John Kuhn; TJ O'Rourke; J Brentzel; W Lynch; S Y King; T D Brown; Daniel Von Hoff
Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies.
Investigational new drugs 1998;16(1):19-27.
1998: Daniel Von Hoff; A L Goodwin; L Garcia
Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team.
British journal of cancer 1998;78 Suppl 3():9-13.
1998: Miguel A Villalona-Calero; John R Eckardt; Howard A Burris; Maura Kraynak; S Fields-Jones; C Bazan; Jack Lancaster; T Hander; R Goldblum; L Hammond; A Bari; Ronald L Drengler; M Rothenberg; G Hadovsky; Daniel Von Hoff
A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(1):71-7.
1998: G R Weiss; Italo POggesi; Maurizio Rocchetti; D DeMaria; T Mooneyham; D Reilly; L V Vitek; F Whaley; E Patricia; Daniel Von Hoff; Peter J O'Dwyer
A phase I and pharmacokinetic study of tallimustine [PNU 152241 (FCE 24517)] in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(1):53-9.
1997: Eric Raymond; Sandrine Faivre; Véronique Dieras; Daniel Von Hoff
[Inhibition of telomeres and telomerase. Seeking for new anticancer drugs].
Bulletin du cancer 1997;84(12):1123-33.
1997: S Sharma; E Raymond; H Soda; D Sun; S G Hilsenbeck; A Sharma; Elzbieta Izbicka; BE Windle; Daniel Von Hoff
Preclinical and clinical strategies for development of telomerase and telomere inhibitors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(11):1063-74.
1997: Eric Raymond; Elzbieta Izbicka; H Soda; S L Gerson; M Dugan; Daniel Von Hoff
Activity of temozolomide against human tumor colony-forming units.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(10):1769-74.
1997: E Raymond; Howard A Burris; eric rowinsky; John R Eckardt; G Rodriguez; L Smith; G Weiss; Daniel Von Hoff
Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(10):1003-8.
1997: S Sharma; E Raymond; H Soda; Daniel Von Hoff
Telomerase and telomere inhibitors in preclinical development.
Expert opinion on investigational drugs 1997;6(9):1179-85.
1997: Daniel Von Hoff
The taxoids: same roots, different drugs.
Seminars in oncology 1997;24(4 Suppl 13):S13-3-S13-10.
1997: X Zhang; Helen M Burt; Gina L Mangold; D Dexter; Daniel Von Hoff; L Mayer; William L Hunter
Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel.
Anti-cancer drugs 1997;8(7):696-701.
1997: Howard A Burris; V C Dieras; M Tunca; R H Earhart; John R Eckardt; Gladys I Rodriguez; D S Shaffer; S M Fields; Elizabeth Campbell; Larry J Schaaf; D Kasunic; Daniel Von Hoff
Phase I study with the DNA sequence-specific agent adozelesin.
Anti-cancer drugs 1997;8(6):588-96.
1997: Eric K Rowinsky; Lon Smith; G Rodriguez; L White; Ronald L Drengler; Daniel Von Hoff; N Peacock; Cheryl Aylesworth; Howard A Burris; Peter M Ravdin; R Bellet
Docetaxel in combination with fluorouracil: study design and preliminary results.
Oncology (Williston Park, N.Y.) 1997;11(6 Suppl 6):33-5.
1997: Howard A Burris; M J Moore; J Andersen; M R Green; Mace L Rothenberg; M R Modiano; M C Cripps; Russell Portenoy; AM Storniolo; P Tarassoff; R Nelson; F A Dorr; CD Stephens; Daniel Von Hoff
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(6):2403-13.
1997: Carla Heise; Adam Sampson-Johannes; A Williams; F McCormick; Daniel Von Hoff; David H Kirn
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents.
Nature medicine 1997;3(6):639-45.
1997: Eric Raymond; A Hanauske; Sandrine Faivre; Elzbieta Izbicka; G Clark; eric rowinsky; Daniel Von Hoff
Effects of prolonged versus short-term exposure paclitaxel (Taxol) on human tumor colony-forming units.
Anti-cancer drugs 1997;8(4):379-85.
1997: Elzbieta Izbicka; R Lawrence; Cesario Cerna; Daniel Von Hoff; P E Sanderson
Activity of TER286 against human tumor colony-forming units.
Anti-cancer drugs 1997;8(4):345-8.
1997: Alexandra M Levine; Anil Tulpule; D Tessman; L Kaplan; Francis Giles; B D Luskey; David T Scadden; Donald W Northfelt; I Silverberg; J Wernz; Byron M Espina; Daniel Von Hoff
Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: results from a multicenter phase II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(3):1094-103.
1997: Geert-Jan Creemers; C J H Gerrits; John R Eckardt; J H M Schellens; Howard A Burris; A S T Planting; Gladys I Rodriguez; Walter J Loos; IR Hudson; C Broom; Jaap Verweij; Daniel Von Hoff
Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(3):1087-93.
1997: John R MacDonald; C C Muscoplat; D L Dexter; Gina L Mangold; S F Chen; Michael J Kelner; Trevor C McMorris; Daniel Von Hoff
Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S.
Cancer research 1997;57(2):279-83.
1997: L Seal; Daniel Von Hoff; R Lawrence; Elzbieta Izbicka; R M Jamison
An in vitro assessment of the antineoplastic potential of 2H-1,3-oxazine-2,6(3H)-dione (3-oxauracil), a novel pyrimidine.
Investigational new drugs 1997;15(4):289-93.
1997: X Zhang; Helen M Burt; Daniel Von Hoff; D Dexter; Gina L Mangold; D Degen; A M Oktaba; William L Hunter
An investigation of the antitumour activity and biodistribution of polymeric micellar paclitaxel.
Cancer chemotherapy and pharmacology 1997;40(1):81-6.
1997: John K Jackson; Weixian Min; Tony F Cruz; S Cindric; L Arsenault; Daniel Von Hoff; D Degan; William L Hunter; Helen M Burt
A polymer-based drug delivery system for the antineoplastic agent bis(maltolato)oxovanadium in mice.
British journal of cancer 1997;75(7):1014-20.
1996: E Raymond; Daekyu Sun; S F Chen; B Windle; Daniel Von Hoff
Agents that target telomerase and telomeres.
Current opinion in biotechnology 1996;7(6):583-91.
1996: M A Izquierdo; D Degen; E Raymond; D Caron; V Ortiz; P Banks; Daniel Von Hoff
Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin 3 fusion protein, on human tumor colony-forming units taken directly from patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(10):1713-6.
1996: Daniel Von Hoff
Gemcitabine: a case study for clinical benefit.
Seminars in oncology 1996;23(5 Suppl 10):1-2.
1996: S Gail Eckhardt; Howard A Burris; John R Eckardt; G Weiss; G Rodriguez; M Rothenberg; David A Rinaldi; R Barrington; John Kuhn; K Masuo; K Sudo; R Atsumi; T Oguma; L Higashi; S Fields; Leslie Ann Smetzer; Daniel Von Hoff
A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(5):491-6.
1996: G R Weiss; D W Shaffer; C DeMoor; David A Rinaldi; Gladys I Rodriguez; John R Eckardt; C Stephens; Daniel Von Hoff
A randomized phase I study of oral etoposide with or without granulocyte-macrophage colony-stimulating factor for the treatment of patients with advanced cancer.
Anti-cancer drugs 1996;7(4):402-9.
1996: M A Izquierdo; D Degen; Joe Sypek; Daniel Von Hoff
Antiproliferative effects of interleukin-12 treatment on human tumor colony-forming units taken directly from patients.
Anti-cancer drugs 1996;7(3):275-80.
1996: Mace L Rothenberg; M J Moore; M C Cripps; J S Andersen; Russell Portenoy; Howard A Burris; M R Green; P G Tarassoff; T D Brown; E S Casper; A M Storniolo; Daniel Von Hoff
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(4):347-53.
1996: Mace L Rothenberg; John R Eckardt; John Kuhn; Howard A Burris; James Nelson; Susan G Hilsenbeck; Gladys I Rodriguez; A M Thurman; L S Smith; S Gail Eckhardt; G R Weiss; Gary L Elfring; David A Rinaldi; Larry J Schaaf; Daniel Von Hoff
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(4):1128-35.
1996: Daniel Von Hoff
"It feels better"--measuring clinical benefit.
European journal of cancer (Oxford, England : 1990) 1996;32A(2):376-7.
1996: Daniel Von Hoff
Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine. San Antonio Drug Development Team.
Investigational new drugs 1996;14(3):265-70.
1996: Daniel Von Hoff
Future directions for clinical research with CPT-11 (irinotecan).
European journal of cancer (Oxford, England : 1990) 1996;32A Suppl 3():S9-12.
1996: Jinee Rizzo; Alexandra M Levine; G R Weiss; T Pearce; Maura Kraynak; R Mueck; S Smith; Daniel Von Hoff; John Kuhn
Pharmacokinetic profile of Mitoguazone (MGBG) in patients with AIDS related non-Hodgkin's lymphoma.
Investigational new drugs 1996;14(2):227-34.
1996: P V Woolley; C J Schultz; G I Rodriguez; Richard Gams; K W Rowe; M L Dadey; Daniel Von Hoff; J J McPhillips
A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma.
Investigational new drugs 1996;14(2):219-22.
1995: John R Eckardt; G Eckhardt; Miguel A Villalona-Calero; Ronald L Drengler; Daniel Von Hoff
New anticancer agents in clinical development.
Oncology (Williston Park, N.Y.) 1995;9(12):1321-8; 1331; discussion 1332-4.
1995: Agop Bedikian; G R Weiss; Sewa S Legha; Howard A Burris; John R Eckardt; J Jenkins; Omar Eton; Antonio C Buzaid; Leslie Ann Smetzer; Daniel Von Hoff
Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(12):2895-9.
1995: Yumay Chen; Chi-Fen Chen; Daniel Riley; D C Allred; Phang-Lang Chen; Daniel Von Hoff; C Kent Osborne; Wen-Hwa Lee
Aberrant subcellular localization of BRCA1 in breast cancer.
Science (New York, N.Y.) 1995;270(5237):789-91.
1995: John R Eckardt; G Eckhardt; Miguel A Villalona-Calero; Ronald L Drengler; Daniel Von Hoff
New anticancer agents in clinical development.
Oncology (Williston Park, N.Y.) 1995;9(11):1191-9.
1995: M A Izquierdo; D Degen; L Myers; D J Levitt; Daniel Von Hoff
Effects of the hematopoietic growth factors GM-CSF, IL-3, and IL-6 on human tumor colony-forming units taken directly from patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(9):927-32.
1995: P S Ritch; C Keever; J Schiller; S Rivkin; P L Witt; Sidney E Grossberg; Robert L Truitt; H Burris; Daniel Von Hoff; L Vaickus
Phase IA/IB evaluation of mammalian cell-derived glycosylated recombinant human interleukin (SIGOSIX) before and after cytotoxic chemotherapy.
Annals of the New York Academy of Sciences 1995;762():359-60.
1995: G C Zimmerman; J H Keeling; H A Burris; G Cook; R Irvin; John Kuhn; ML McCollough; Daniel Von Hoff
Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent.
Archives of dermatology 1995;131(2):202-6.
1995: Richard M Elledge; Gary M Clark; J Hon; M Thant; R Belt; Y P Maguire; J Brown; P Bartels; Daniel Von Hoff
Rapid in vitro assay for predicting response to fluorouracil in patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(2):419-23.
1995: C Van Den Berg; X Y Guan; Daniel Von Hoff; R Jenkins; Constance A Griffin; Olli Kallioniemi; J Herath
DNA sequence amplification in human prostate cancer identified by chromosome microdissection: potential prognostic implications.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(1):11-8.
1995: A A Ebrahim el-Zayat; M A Izquierdo; G M Clark; Daniel Von Hoff
Activity of the morpholino anthracycline 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin (MX2) against human tumor colony-forming units in vitro.
Investigational new drugs 1995;13(2):125-131.
1995: C Van den Berg; Daniel Von Hoff
Use of hydroxyurea to alter drug resistance of human tumor cells.
Cancer treatment and research 1995;78():95-114.
1995: G R Weiss; John Kuhn; Jinee Rizzo; L S Smith; Gladys I Rodriguez; John R Eckardt; Howard A Burris; S Fields; K VanDenBerg; Daniel Von Hoff
A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors.
Cancer chemotherapy and pharmacology 1995;35(5):397-402.
1995: Daniel Von Hoff
New agent development for women with breast cancer.
Cancer investigation 1995;13(3):341-4.
1995: Axel R Hanauske; G M Clark; Daniel Von Hoff
Adenocarcinoma of unknown primary: retrospective analysis of chemosensitivity of 313 freshly explanted tumors in a tumor cloning system.
Investigational new drugs 1995;13(1):43-9.
1995: M V Marshall; K D Carey; Daniel Von Hoff; John Kuhn
Hepsulfam distribution in blood, plasma and cerebrospinal fluid of baboons.
Investigational new drugs 1995;13(1):33-6.
1994: P W Cobb; D R Degen; G M Clark; S F Chen; John Kuhn; J L Gross; M R Kirshenbaum; J H Sun; Howard A Burris; Daniel Von Hoff
Activity of DMP 840, a new bis-naphthalimide, on primary human tumor colony-forming units.
Journal of the National Cancer Institute 1994;86(19):1462-5.
1994: C L Van den Berg; J R McGill; John Kuhn; J T Walsh; P S De La Cruz; K K Davidson; Geoffrey M Wahl; Daniel Von Hoff
Pharmacokinetics of hydroxyurea in nude mice.
Anti-cancer drugs 1994;5(5):573-8.
1994: Howard A Burris; A Awada; John Kuhn; John R Eckardt; P W Cobb; David A Rinaldi; S Fields; L Smith; Daniel Von Hoff
Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion.
Anti-cancer drugs 1994;5(4):394-402.
1994: S G Eckhardt; A Dai; K K Davidson; B J Forseth; Geoffrey M Wahl; Daniel Von Hoff
Induction of differentiation in HL60 cells by the reduction of extrachromosomally amplified c-myc.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(14):6674-8.
1994: Daniel Von Hoff
MGBG: teaching an old drug new tricks.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(6):487-93.
1994: K J Martin; S F Chen; G M Clark; D Degen; M Wajima; Daniel Von Hoff; R Kaddurah-Daouk
Evaluation of creatine analogues as a new class of anticancer agents using freshly explanted human tumor cells.
Journal of the National Cancer Institute 1994;86(8):608-13.
1994: G C Zimmerman; J H Keeling; M Lowry; J Medina; Daniel Von Hoff; H A Burris
Prevention of docetaxel-induced erythrodysesthesia with local hypothermia.
Journal of the National Cancer Institute 1994;86(7):557-8.
1994: Y Shimada; M Rothenberg; S G Hilsenbeck; Howard A Burris; D Degen; Daniel Von Hoff
Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units.
Anti-cancer drugs 1994;5(2):202-6.
1994: John R Eckardt; Daniel Von Hoff
New drugs in clinical development in the United States.
Hematology/oncology clinics of North America 1994;8(2):305-32.
1994: D Yee; James G Jackson; Daniel Von Hoff; Peter M Ravdin
Case report: use of insulin-like growth factor-I gene expression to distinguish between breast and ovarian cancer.
The American journal of the medical sciences 1994;307(2):108-11.
1994: John R Eckardt; Howard A Burris; John Kuhn; MC Bissery; M Klink-Alakl; Gary M Clark; Daniel Von Hoff
Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vitro.
Journal of the National Cancer Institute 1994;86(1):30-3.
1994: T J O'Rourke; T D Brown; K Havlin; John Kuhn; J B Craig; Howard A Burris; W G Satterlee; P G Tarassoff; Daniel Von Hoff
Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days.
European journal of cancer (Oxford, England : 1990) 1994;30A(3):417-8.
1994: Daniel Von Hoff; Howard A Burris; John R Eckardt; M Rothenberg; S M Fields; S F Chen; John Kuhn
Preclinical and phase I trials of topoisomerase I inhibitors.
Cancer chemotherapy and pharmacology 1994;34 Suppl():S41-5.
1994: Suzanne A W Fuqua; Steffi Oesterreich; Susan G Hilsenbeck; Daniel Von Hoff; J Eckardt; C Kent Osborne
Heat shock proteins and drug resistance.
Breast cancer research and treatment 1994;32(1):67-71.
1993: J R McGill; Brett Beitzel; J L Nielsen; J T Walsh; S M Drabek; R J Meador; Daniel Von Hoff
Double minutes are frequently found in ovarian carcinomas.
Cancer genetics and cytogenetics 1993;71(2):125-31.
1993: M F Sarosdy; D H Hutzler; D Yee; Daniel Von Hoff
In vitro sensitivity testing of human bladder cancers and cell lines to TP-40, a hybrid protein with selective targeting and cytotoxicity.
The Journal of urology 1993;150(6):1950-5.
1993: Thomas C Hardin; J M Koeller; John Kuhn; David G Roodman; Daniel Von Hoff
Nutritional parameters observed during 28-day infusion of recombinant human tumor necrosis factor-alpha.
JPEN. Journal of parenteral and enteral nutrition 1993;17(6):541-5.
1993: J Sharma; Daniel Von Hoff; G R Weiss
Salmonella arizonae peritonitis secondary to ingestion of rattlesnake capsules for gastric cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(11):2288-9.
1993: Douglas Adkins; CE Encarnacion; D Salzman; D Boldt; Cesar O Freytes; Daniel Von Hoff; Charles F LeMaistre
Durable complete remission in a patient with refractory mediastinal non-seminomatous germ cell tumor after tandem high-dose chemotherapy and autologous bone marrow transplantation.
Bone marrow transplantation 1993;12(5):541-6.
1993: S J Vukelja; W J Baker; H A Burris; J H Keeling; Daniel Von Hoff
Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere.
Journal of the National Cancer Institute 1993;85(17):1432-3.
1993: Kathy S Albain; John J Crowley; Laura F Hutchins; David R Gandara; R M O'Bryan; Daniel Von Hoff; B Griffin; Robert B Livingston
Predictors of survival following relapse or progression of small cell lung cancer. Southwest Oncology Group Study 8605 report and analysis of recurrent disease data base.
Cancer 1993;72(4):1184-91.
1993: H Choy; F F Rodriguez; S Koester; S Hilsenbeck; Daniel Von Hoff
Investigation of taxol as a potential radiation sensitizer.
Cancer 1993;71(11):3774-8.
1993: M V Marshall; G Driskill-Kasprowicz; Daniel Von Hoff; A R Hanauske
Stability of extrachromosomal DNA after different storage conditions.
BioTechniques 1993;14(5):737-9.
1993: J H Saiki; W J Stuckey; J W Athens; B L Tranum; E Van Slyck; Daniel Von Hoff
Mitoxantrone (dihydroxyanthracenedione) in acute leukemia. An evaluation of two treatment schedules by the Southwest Oncology Group.
Investigational new drugs 1993;11(2-3):197-200.
1993: Douglas Adkins; R Irvin; John Kuhn; D H Boldt; David G Roodman; D Salzman; Cesar O Freytes; Daniel Von Hoff; Charles F LeMaistre
A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors.
Investigational new drugs 1993;11(2-3):169-79.
1993: G Rodriguez; T D Brown; FRANK BALIS; J B Craig; C A Denham; John Kuhn; K Havlin; Daniel Von Hoff
A phase I trial of trimetrexate (NSC352122) on a daily x 5 schedule in patients with refractory adult leukemia.
Anti-cancer drugs 1993;4(2):163-6.
1993: F Thiebaut; A R Hanauske; Daniel Von Hoff
Evidence for binding of extrachromosomal DNA sequences to nuclear matrix proteins in multidrug-resistant KB-V1 cells.
FEBS letters 1993;319(1-2):133-7.
1993: David A Rinaldi; S M Lippman; Howard A Burris; C Chou; Daniel Von Hoff; Waun Ki Hong
Phase II study of 13-cis-retinoic acid and interferon-alpha 2a in patients with advanced squamous cell lung cancer.
Anti-cancer drugs 1993;4(1):33-6.
1993: A A el-Zayat; D Degen; S Drabek; G M Clark; George R Pettit; Daniel Von Hoff
In vitro evaluation of the antineoplastic activity of combretastatin A-4, a natural product from Combretum caffrum (arid shrub).
Anti-cancer drugs 1993;4(1):19-25.
1993: J L Nielsen; J T Walsh; D R Degen; S M Drabek; J R McGill; Daniel Von Hoff
Evidence of gene amplification in the form of double minute chromosomes is frequently observed in lung cancer.
Cancer genetics and cytogenetics 1993;65(2):120-4.
1993: Narin Voravud; Scott M Lippman; Randal S Weber; G I Rodriquez; D Yee; I W Dimery; C L Earley; Daniel Von Hoff; Waun Ki Hong
Phase II trial of 13-cis-retinoic acid plus interferon-alpha in recurrent head and neck cancer.
Investigational new drugs 1993;11(1):57-60.
1993: G R Weiss; T D Brown; John Kuhn; Daniel Von Hoff; R H Earhart; Wade J Adams; J E Brewer; J D Hosley; D A Kasunic
A phase I clinical and pharmacokinetic study of the oral and the oral/intravenous administration of menogaril.
Investigational new drugs 1993;11(1):17-27.
1993: M V Marshall; M H Marshall; D R Degen; David G Roodman; John Kuhn; M E Ross; Daniel Von Hoff
In vitro cytotoxicity of hepsulfam against human tumor cell lines and primary human tumor colony forming units.
Stem cells (Dayton, Ohio) 1993;11(1):62-9.
1993: A R Hanauske; M Ross; D Degen; S G Hilsenbeck; Daniel Von Hoff
In vitro activity of the benzotriazine dioxide SR 4233 against human tumour colony-forming units.
European journal of cancer (Oxford, England : 1990) 1993;29A(3):423-5.
1993: R F Krywicki; J A Figueroa; James G Jackson; T W Kozelsky; S Shimasaki; Daniel Von Hoff; D Yee
Regulation of insulin-like growth factor binding proteins in ovarian cancer cells by oestrogen.
European journal of cancer (Oxford, England : 1990) 1993;29A(14):2015-9.
1992: Howard A Burris; A R Hanauske; R K Johnson; M H Marshall; John Kuhn; S G Hilsenbeck; Daniel Von Hoff
Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro.
Journal of the National Cancer Institute 1992;84(23):1816-20.
1992: Daniel Von Hoff; J McGill; K Davidson; B Forseth; A Atef Ebrahim el-Zayat; Howard A Burris
Preclinical leads for innovative uses for etoposide.
Seminars in oncology 1992;19(6 Suppl 13):10-3.
1992: D R VanDevanter; G Yirdaw; C Do; K A Tysseling; C A Drescher; B J Forseth; Daniel Von Hoff; M A McNutt
Preparation of uniform, intact DNA samples from resected tumor tissues for pulsed-field gel electrophoretic analyses.
BioTechniques 1992;13(6):884-7.
1992: Howard A Burris; Mace L Rothenberg; John Kuhn; Daniel Von Hoff
Clinical trials with the topoisomerase I inhibitors.
Seminars in oncology 1992;19(6):663-9.
1992: T J Melink; G M Clark; Daniel Von Hoff
The impact of phase I clinical trials on the quality of life of patients with cancer.
Anti-cancer drugs 1992;3(6):571-6.
1992: A R Hanauske; D Degen; M H Marshall; P P Trotta; Daniel Von Hoff
Lack of effects of recombinant human interleukin-4 on in vitro colony formation of freshly explanted human tumor cells.
Investigational new drugs 1992;10(4):269-73.
1992: Tatyana A Holzmayer; S Hilsenbeck; Daniel Von Hoff; Igor B Roninson
Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas.
Journal of the National Cancer Institute 1992;84(19):1486-91.
1992: Daniel Von Hoff; J R McGill; B J Forseth; K K Davidson; T P Bradley; D R Van Devanter; Geoffrey M Wahl
Elimination of extrachromosomally amplified MYC genes from human tumor cells reduces their tumorigenicity.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(17):8165-9.
1992: J G Wall; Howard A Burris; Daniel Von Hoff; G Rodriguez; Rayna Kneuper-Hall; D Shaffer; T O'Rourke; T Brown; G Weiss; G Clark
A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days.
Anti-cancer drugs 1992;3(4):337-45.
1992: J R McGill; P J Lalley; Robin J Leach; T J Johnson; Daniel Von Hoff
Chromosomal influence on hybrid cell proliferation.
Cell proliferation 1992;25(4):345-55.
1992: Bruce H Haughey; Daniel Von Hoff; B E Windle; Geoffrey M Wahl; P M Mock
c-myc oncogene copy number in squamous carcinoma of the head and neck.
American journal of otolaryngology 1992;13(3):168-71.
1992: Daniel Von Hoff; M H Marshall; David C Heimbrook; S M Stirdivant; J D Ahern; W K Herbert; R Z Maigetter; Allen Oliff
Activity of a recombinant transforming growth factor-alpha-Pseudomonas exotoxin hybrid protein against primary human tumor colony-forming units.
Investigational new drugs 1992;10(1):17-22.
1992: A R Hanauske; D Degen; M H Marshall; S G Hilsenbeck; G B Grindey; Daniel Von Hoff
Activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human tumor colony forming units.
Anti-cancer drugs 1992;3(2):143-6.
1992: A R Hanauske; D Degen; M H Marshall; S G Hilsenbeck; P Banks; J Stuckey; M Leahy; Daniel Von Hoff
Effects of recombinant human interleukin-1 alpha on clonogenic growth of primary human tumors in vitro.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;11(3):155-8.
1992: A R Hanauske; D Degen; S G Hilsenbeck; M C Bissery; Daniel Von Hoff
Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells.
Anti-cancer drugs 1992;3(2):121-4.
1992: W J Slichenmyer; C F LeMaistre; Daniel Von Hoff
Response of metastatic adenoid cystic carcinoma and Merkel cell tumor to high-dose melphalan with autologous bone marrow transplantation.
Investigational new drugs 1992;10(1):45-8.
1992: G J Harris; Gary M Clark; Daniel Von Hoff
Hispanic patients with head and neck cancer do not have a worse prognosis than Anglo-American patients.
Cancer 1992;69(4):1003-7.
1992: A R Hanauske; D Degen; M H Marshall; S G Hilsenbeck; J J McPhillips; Daniel Von Hoff
Preclinical activity of ilmofosine against human tumor colony forming units in vitro.
Anti-cancer drugs 1992;3(1):43-6.
1992: B K Bhuyan; K S Smith; E G Adams; T L Wallace; Daniel Von Hoff; L H Li
Adozelesin, a potent new alkylating agent: cell-killing kinetics and cell-cycle effects.
Cancer chemotherapy and pharmacology 1992;30(5):348-54.
1991: Peter M Ravdin; K A Havlin; M V Marshall; T D Brown; J M Koeller; John Kuhn; G Rodriguez; Daniel Von Hoff
A phase I clinical and pharmacokinetic trial of hepsulfam.
Cancer research 1991;51(23 Pt 1):6268-72.
1991: W J Slichenmyer; Daniel Von Hoff
Taxol: a new and effective anti-cancer drug.
Anti-cancer drugs 1991;2(6):519-30.
1991: Daniel Von Hoff; T Waddelow; B Forseth; K Davidson; J Scott; G Wahl
Hydroxyurea accelerates loss of extrachromosomally amplified genes from tumor cells.
Cancer research 1991;51(23 Pt 1):6273-9.
1991: Daniel Von Hoff
In vitro data supporting interferon plus cytotoxic agent combinations.
Seminars in oncology 1991;18(5 Suppl 7):58-61.
1991: D Yee; F R Morales; T C Hamilton; Daniel Von Hoff
Expression of insulin-like growth factor I, its binding proteins, and its receptor in ovarian cancer.
Cancer research 1991;51(19):5107-12.
1991: Giampietro Gasparini; S Dal Fior; F Pozza; G A Panizzoni; S Favretto; Daniel Von Hoff
Phase I study of escalating dose mitoxantrone in combination with alpha-2-interferon in patients with advanced solid tumors.
Investigational new drugs 1991;9(3):245-52.
1991: T Brown; K Havlin; Geoffrey Weiss; J Cagnola; J Koeller; John Kuhn; Jinee Rizzo; J Craig; J Phillips; Daniel Von Hoff
A phase I trial of taxol given by a 6-hour intravenous infusion.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(7):1261-7.
1991: Daniel Von Hoff; S Green; D S Alberts; D L Stock-Novack; E A Surwit; T P Miller; R L Stephens
Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced endometrial cancer. A Southwest Oncology Group Study.
American journal of clinical oncology 1991;14(3):193-4.
1991: Daniel Von Hoff; S J Green; J A Neidhart; C Fabian; T Budd; J F Boyd; C Kent Osborne
Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. A Southwest Oncology Group study.
Investigational new drugs 1991;9(1):87-8.
1991: Daniel Von Hoff; J Turner
Response rates, duration of response, and dose response effects in phase I studies of antineoplastics.
Investigational new drugs 1991;9(1):115-22.
1991: S E Benner; G M Wahl; Daniel Von Hoff
Double minute chromosomes and homogeneously staining regions in tumors taken directly from patients versus in human tumor cell lines.
Anti-cancer drugs 1991;2(1):11-25.
1991: Julie A Kish; K Kopecky; M K Samson; Daniel Von Hoff; W S Fletcher; R A Kempf; F M Muggia
Evaluation of fludarabine phosphate in malignant melanoma. A Southwest Oncology Group study.
Investigational new drugs 1991;9(1):105-8.
1991: K A Havlin; John Kuhn; J B Craig; D H Boldt; G R Weiss; J Koeller; G Harman; R Schwartz; G N Clark; Daniel Von Hoff
Phase I clinical and pharmacokinetic trial of flavone acetic acid.
Journal of the National Cancer Institute 1991;83(2):124-8.
1991: Daniel Von Hoff; R Kronmal; S E Salmon; J Turner; J B Green; J S Bonorris; E L Moorhead; H E Hynes; R E Pugh; R J Belt
A Southwest Oncology Group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancer.
Cancer 1991;67(1):20-7.
1991: Daniel Von Hoff
Intraosseous infusions: an important but forgotten method of vascular access.
Cancer investigation 1991;9(5):521-8.
1991: Daniel Von Hoff
New mechanisms of gene amplification in drug resistance (the episome model).
Cancer treatment and research 1991;57():1-11.
1991: M Van Nguyen; G M Clark; D Mascorro; Daniel Von Hoff
In-vitro chemosensitivity testing of human gastric adenocarcinoma.
Cancer treatment and research 1991;55():133-42.
1990: D R VanDevanter; V D Piaskowski; J T Casper; E C Douglass; Daniel Von Hoff
Ability of circular extrachromosomal DNA molecules to carry amplified MYCN proto-oncogenes in human neuroblastomas in vivo.
Journal of the National Cancer Institute 1990;82(23):1815-21.
1990: Daniel Von Hoff; John Kuhn; K A Havlin; Anne-Marie Langevin; T D Brown; G R Weiss; J N Turner; J Purvis; V S Lucas; K W Bair
Phase I and clinical pharmacology trial of 502U83 using a monthly single dose schedule.
Cancer research 1990;50(23):7496-500.
1990: Daniel Von Hoff; T R Fleming; J S Macdonald; P J Goodman; J Van Damme; T D Brown; T O'Rourke; Lynn Feun; M D Keppen
Phase II evaluation of recombinant gamma-interferon in patients with advanced pancreatic carcinoma: a Southwest Oncology Group study.
Journal of biological response modifiers 1990;9(6):584-7.
1990: A Dinesman; Bruce H Haughey; George A Gates; T Aufdemorte; Daniel Von Hoff
Development of a new in vivo model for head and neck cancer.
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 1990;103(5 ( Pt 1)):766-74.
1990: M Keaton; T Brown; J Craig; G Fries; G Harmon; A Zaloznik; G Orczyk; Daniel Von Hoff
Phase II study of carbetimer in non-small cell lung cancer.
Investigational new drugs 1990;8(4):385-6.
1990: S Fields; J Koeller; R L Topper; G Guritz; Daniel Von Hoff
Local soft tissue toxicity following cisplatin extravasation.
Journal of the National Cancer Institute 1990;82(20):1649-50.
1990: Daniel Von Hoff; B Metch; J G Lucas; S P Balcerzak; S M Grunberg; S E Rivkin
Phase II evaluation of recombinant interferon-beta (IFN-beta ser) in patients with diffuse mesothelioma: a Southwest Oncology Group study.
Journal of interferon research 1990;10(5):531-4.
1990: R S Foulke; M H Marshall; P P Trotta; Daniel Von Hoff
In vitro assessment of the effects of granulocyte-macrophage colony-stimulating factor on primary human tumors and derived lines.
Cancer research 1990;50(19):6264-7.
1990: Daniel Von Hoff; S Green; E A Surwit; E V Hannigan; D S Alberts
Phase II study of fludarabine phosphate (NSC 312887) in patients with advanced cervical cancer. A Southwest Oncology Group study.
American journal of clinical oncology 1990;13(5):433-5.
1990: Daniel Von Hoff
Phase I clinical trials with fludarabine phosphate.
Seminars in oncology 1990;17(5 Suppl 8):33-8.
1990: F J Mather; R M Simon; G M Clark; Daniel Von Hoff
A method for the evaluation of dose-toxicity relationships in clinical trials.
Statistics in medicine 1990;9(9):1117-8.
1990: W J Slichenmyer; Daniel Von Hoff
New natural products in cancer chemotherapy.
Journal of clinical pharmacology 1990;30(9):770-88.
1990: K E Noonan; C Beck; Tatyana A Holzmayer; J E Chin; J S Wunder; Irene L Andrulis; A F Gazdar; C L Willman; B Griffith; Daniel Von Hoff
Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(18):7160-4.
1990: Daniel Von Hoff; S Dahlberg; R J Hartstock; H J Eyre
Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: a Southwest Oncology Group study.
Journal of the National Cancer Institute 1990;82(16):1353-5.
1990: Raymond B Weiss; Ross C Donehower; P H Wiernik; T Ohnuma; R J Gralla; D L Trump; James R Baker Jr; David A Van Echo; Daniel Von Hoff; Brian Leyland-Jones
Hypersensitivity reactions from taxol.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(7):1263-8.
1990: Daniel Von Hoff; B Forseth; C N Clare; K L Hansen; D VanDevanter
Double minutes arise from circular extrachromosomal DNA intermediates which integrate into chromosomal sites in human HL-60 leukemia cells.
The Journal of clinical investigation 1990;85(6):1887-95.
1990: Daniel Von Hoff; P J Goodman; C A Presant; R L Ruxer; J S MacDonald; J J Costanzi; R L Stephens; S J Vogel
A phase II trial of continuous infusion vinblastine in patients with gastric carcinoma. A Southwest Oncology Group study.
European journal of cancer (Oxford, England : 1990) 1990;26(3):405-7.
1990: N Oishi; T R Fleming; L Laufman; J S Ungerleider; R B Natale; A B Einstein; Daniel Von Hoff; J S Macdonald
VM-26 in colorectal carcinoma: a Southwest Oncology Group study.
Investigational new drugs 1990;8(1):93-5.
1990: Sarah A Taylor; T Fleming; Daniel Von Hoff; J D McCracken; R M Bukowski; R W Talley; R B Natale; J T Guy; W E Samlowski; J H Costanzi
Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: a Southwest Oncology Group study.
Investigational new drugs 1990;8(1):77-80.
1990: D E Mattox; Daniel Von Hoff; S P Balcerzak
Southwest Oncology Group study of mitoxantrone for treatment of patients with advanced adenoid cystic carcinoma of the head and neck.
Investigational new drugs 1990;8(1):105-7.
1990: Daniel Von Hoff
He's not going to talk about in vitro predictive assays again, is he?
Journal of the National Cancer Institute 1990;82(2):96-101.
1990: Daniel Von Hoff; J F Sandbach; Gary M Clark; J N Turner; B F Forseth; M J Piccart; N Colombo; F M Muggia
Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician.
Journal of the National Cancer Institute 1990;82(2):110-6.
1990: T J Melink; G Sarosy; A R Hanauske; J L Phillips; J H Bayne; M R Grever; H N Jayaram; Daniel Von Hoff
Phase I trial and biochemical evaluation of tiazofurin administered on a weekly schedule.
Selective cancer therapeutics 1990;6(1):51-61.
1990: T D Brown; K A Havlin; J M Koeller; John Kuhn; T J O'Rourke; Gladys I Rodriguez; G R Weiss; Daniel Von Hoff
New anticancer agents.
Cancer chemotherapy and biological response modifiers 1990;11():115-41.
1990: Daniel Von Hoff; B A Blumenstein; T W Pollock; E D Crawford; J K Weick; J T Guy; Mario A Eisenberger; W S Fletcher; R B Natale
Methylglyoxal bis-guanylhydrazone in advanced bladder cancer.
European journal of cancer (Oxford, England : 1990) 1990;26(7):848-9.
1990: Jinee Rizzo; C Riley; Daniel Von Hoff; John Kuhn; J Phillips; T Brown
Analysis of anticancer drugs in biological fluids: determination of taxol with application to clinical pharmacokinetics.
Journal of pharmaceutical and biomedical analysis 1990;8(2):159-64.
1990: D R Van Devanter; Daniel Von Hoff
Acid depurination after field inversion agarose gel electrophoresis reduces transfer of large DNA molecules.
Applied and theoretical electrophoresis : the official journal of the International Electrophoresis Society 1990;1(4):189-92.
1989: G R Weiss; G A Sarosy; T D Shenkenberg; T Williams; N J Clendeninn; Daniel Von Hoff; JL Woolley; S H Liao; M R Blum
A phase I clinical and pharmacological study of weekly intravenous infusions of piritrexim (BW301U).
European journal of cancer & clinical oncology 1989;25(12):1867-73.
1989: Michael F Sarosdy; L H Einhorn; J P Donohue; Daniel Von Hoff
Correlation of clonogenic growth with histologic diagnosis after resection of residual tissue following chemotherapy for nonseminomatous testis cancer.
Urology 1989;34(6):396-8.
1989: Bernd Lathan; K Kerkhoff; W Scheithauer; Daniel Von Hoff; Volker Diehl
Homogeneous growth of tumor cell colonies in agar containing glass capillaries.
Anticancer research 1989;9(6):1897-902.
1989: Carlos L Arteaga; T D Brown; John Kuhn; H S Shen; T J O'Rourke; K Beougher; H J Brentzel; Daniel Von Hoff; G R Weiss
Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
Cancer research 1989;49(16):4648-53.
1989: F J Mather; R M Simon; G M Clark; Daniel Von Hoff
A method for the evaluation of dose-toxicity relationships in clinical trials.
Statistics in medicine 1989;8(7):813-23.
1989: John Kuhn; Daniel Von Hoff; M Hersh; T Melink; Gary M Clark; G R Weiss; C A Coltman
Phase I trial of echinomycin (NSC 526417), a bifunctional intercalating agent, administered by 24-hour continuous infusion.
European journal of cancer & clinical oncology 1989;25(5):797-803.
1989: J W Wallen; R L Cate; D M Kiefer; M W Riemen; D Martinez; R M Hoffman; P K Donahoe; Daniel Von Hoff; B Pepinsky; Allen Oliff
Minimal antiproliferative effect of recombinant müllerian inhibiting substance on gynecological tumor cell lines and tumor explants.
Cancer research 1989;49(8):2005-11.
1989: G J Harris; F O Tio; Daniel Von Hoff
Primary adrenal lymphoma.
Cancer 1989;63(4):799-803.
1989: K A Havlin; John Kuhn; J W Myers; R F Ozols; D E Mattox; G M Clark; Daniel Von Hoff
High-dose cisplatin for locally advanced or metastatic head and neck cancer. A phase II pilot study.
Cancer 1989;63(3):423-7.
1989: D R Van Devanter; H M Trammell; Daniel Von Hoff
Simple construction of rubber-based agarose block molds for pulsed-field electrophoresis.
BioTechniques 1989;7(2):143-4.
1989: Robert T Dorr; J D Liddil; Daniel Von Hoff; M Soble; C Kent Osborne
Antitumor activity and murine pharmacokinetics of parenteral acronycine.
Cancer research 1989;49(2):340-4.
1989: J L Phillips; R Schwartz; Daniel Von Hoff
In vitro distribution of diacetyl didemnin B in human blood cells and plasma.
Cancer investigation 1989;7(2):123-8.
1989: Bernd Lathan; Daniel Von Hoff; G M Clark; E E Elslager
Evaluation of an amsacrine analog in a human tumor cloning system.
Cancer chemotherapy and pharmacology 1989;24(4):230-2.
1989: J C Ruiz; K H Choi; Daniel Von Hoff; I B Roninson; Geoffrey M Wahl
Autonomously replicating episomes contain mdr1 genes in a multidrug-resistant human cell line.
Molecular and cellular biology 1989;9(1):109-15.
1989: U Hanauske; A R Hanauske; Gary M Clark; D Tsen; J Buchok; Daniel Von Hoff
A new in vitro screening system for anticancer drugs for the treatment of non-small cell lung cancer.
Selective cancer therapeutics 1989;5(3):97-111.
1988: Daniel Von Hoff; A M Huong
Effect of recombinant interferon-beta ser on primary human tumor colony-forming units.
Journal of interferon research 1988;8(6):813-20.
1988: Daniel Von Hoff
Human tumor cloning assays: applications in clinical oncology and new antineoplastic agent development.
Cancer metastasis reviews 1988;7(4):357-71.
1988: Bernd Lathan; V Diehl; G M Clark; Daniel Von Hoff
Cytotoxic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5-monophosphate (fludarabine, NSC 312887) in a human tumor cloning system.
European journal of cancer & clinical oncology 1988;24(12):1891-5.
1988: F A Dorr; John Kuhn; J Phillips; Daniel Von Hoff
Phase I clinical and pharmacokinetic investigation of didemnin B, a cyclic depsipeptide.
European journal of cancer & clinical oncology 1988;24(11):1699-706.
1988: W L McGuire; D H Kern; Daniel Von Hoff; L M Weisenthal
In vitro assays to predict drug sensitivity and drug resistance. A panel discussion.
Breast cancer research and treatment 1988;12(1):7-21.
1988: Carlos L Arteaga; A R Hanauske; Gary M Clark; C Kent Osborne; P Hazarika; R L Pardue; F Tio; Daniel Von Hoff
Immunoreactive alpha transforming growth factor activity in effusions from cancer patients as a marker of tumor burden and patient prognosis.
Cancer research 1988;48(17):5023-8.
1988: Carlos L Arteaga; A K Tandon; Daniel Von Hoff; C Kent Osborne
Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells.
Cancer research 1988;48(14):3898-904.
1988: Daniel Von Hoff; D R Needham-VanDevanter; J Yucel; B E Windle; Geoffrey M Wahl
Amplified human MYC oncogenes localized to replicating submicroscopic circular DNA molecules.
Proceedings of the National Academy of Sciences of the United States of America 1988;85(13):4804-8.
1988: A R Hanauske; U Hanauske; J Buchok; Daniel Von Hoff
Recombinant human transforming growth factor-alpha stimulates in vitro colony formation of fresh human tumor specimens.
International journal of cell cloning 1988;6(3):221-9.
1988: A R Hanauske; Carlos L Arteaga; Gary M Clark; J Buchok; M Marshall; P Hazarika; R L Pardue; Daniel Von Hoff
Determination of transforming growth factor activity in effusions from cancer patients.
Cancer 1988;61(9):1832-7.
1988: S M Lippman; J F Kessler; M Al-Sarraf; D S Alberts; L M Itri; D Mattox; Daniel Von Hoff; Lois J Loescher; Frank L Meyskens
Treatment of advanced squamous cell carcinoma of the head and neck with isotretinoin: a phase II randomized trial.
Investigational new drugs 1988;6(1):51-6.
1988: S M Carroll; Margaret De Rose; Patrick Gaudray; C M Moore; D R Needham-Vandevanter; Daniel Von Hoff; Geoffrey M Wahl
Double minute chromosomes can be produced from precursors derived from a chromosomal deletion.
Molecular and cellular biology 1988;8(4):1525-33.
1988: Daniel Von Hoff; R Kronmal; R V O'Toole; E A Surwit; J J Hutton; D S Alberts
Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced ovarian cancer. A Southwest Oncology Group Study.
American journal of clinical oncology 1988;11(2):146-8.
1988: Arnaldo Pinelli; Silvio Trivulzio; Daniel Von Hoff; D Monti; P Manitto
Observations on the chemical structure and cytotoxic activity of marycin, a hematoporphyrin derivative.
Cancer letters 1988;38(3):257-69.
1988: W Scheithauer; Mary Pat Moyer; G M Clark; Daniel Von Hoff
Application of a new preclinical drug screening system for cancer of the large bowel.
Cancer chemotherapy and pharmacology 1988;21(1):31-4.
1988: H R Metelmann; Daniel Von Hoff
[Anti-oncogram-assisted treatment planning in malignant melanoma].
Fortschritte der Kiefer- und Gesichts-Chirurgie 1988;33():168-70.
1988: J Stein; S Strandjord; U Saarinen; Phyllis I Warkentin; Stanton L Gerson; H Lazarus; Daniel Von Hoff; P Coccia; Nai-Kong V Cheung
In vitro treatment of autologous bone marrow for neuroblastoma patients with anti GD2 monoclonal antibody and human complement: a pilot study.
Progress in clinical and biological research 1988;271():237-48.
1988: G R Weiss; Carlos L Arteaga; T D Brown; J B Craig; G S Harman; K A Havlin; J M Koeller; John Kuhn; Daniel Von Hoff
New anticancer agents.
Cancer chemotherapy and biological response modifiers 1988;10():85-116.
1988: Michael R Grever; K J Kopecky; C A Coltman; J C Files; B R Greenberg; J J Hutton; R Talley; Daniel Von Hoff; S P Balcerzak
Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia.
Nouvelle revue française d'hématologie 1988;30(5-6):457-9.
1987: R J Mercier; G D Neal; D E Mattox; G A Gates; T C Pomeroy; Daniel Von Hoff
Cisplatin and 5-fluorouracil chemotherapy in advanced or recurrent squamous cell carcinoma of the head and neck.
Cancer 1987;60(11):2609-12.
1987: Arnaldo Pinelli; Silvio Trivulzio; Daniel Von Hoff; L Warfel
Comparison of two methods to evaluate drug-cytotoxicity on tumor cell lines cultured in vitro.
Pharmacological research communications 1987;19(12):913-23.
1987: Carlos L Arteaga; B J Forseth; Gary M Clark; Daniel Von Hoff
A radiometric method for evaluation of chemotherapy sensitivity: results of screening a panel of human breast cancer cell lines.
Cancer research 1987;47(23):6248-53.
1987: W H Harvey; T R Fleming; Daniel Von Hoff; J G Katterhagen; C A Coltman
Phase II study of fludarabine phosphate in previously untreated patients with colorectal carcinoma: a Southwest Oncology Group Study.
Cancer treatment reports 1987;71(12):1319-20.
1987: G B Weiss; B Metch; Daniel Von Hoff; Sarah A Taylor; J H Saiers
Phase II trial of fludarabine phosphate in patients with head and neck cancer: a Southwest Oncology Group Study.
Cancer treatment reports 1987;71(12):1313-4.
1987: Carlos L Arteaga; D L Kisner; A Goodman; Daniel Von Hoff
Elliptinium, a DNA intercalating agent with broad antitumor activity in a human tumor cloning system.
European journal of cancer & clinical oncology 1987;23(11):1621-6.
1987: W H Harvey; T R Fleming; G Beltran; J H Saiers; N Oishi; Daniel Von Hoff
Phase II study of fludarabine phosphate in previously untreated patients with hepatoma: a Southwest Oncology Group Study.
Cancer treatment reports 1987;71(11):1111-2.
1987: P K Lillis; T D Brown; K Beougher; J Koeller; S G Marcus; Daniel Von Hoff
Phase II trial of recombinant beta interferon in advanced colorectal cancer.
Cancer treatment reports 1987;71(10):965-7.
1987: Arnaldo Pinelli; Silvio Trivulzio; Daniel Von Hoff; L E Warfel
Cytotoxic effects and physicochemical properties of marycin: a new hematoporphyrin derivative.
European journal of cancer & clinical oncology 1987;23(9):1289-96.
1987: Judith Leopold; S V Scavone; C D Pinter; K L Hamelehle; Daniel Von Hoff; R C Jackson
Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro.
Cancer research 1987;47(16):4299-304.
1987: A R Hanauske; U Hanauske; Daniel Von Hoff
Recent improvements in the human tumor cloning assay for sensitivity testing of antineoplastic agents.
European journal of cancer & clinical oncology 1987;23(6):603-5.
1987: F J Mather; R M Simon; G M Clark; Daniel Von Hoff
Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group phase II studies.
Cancer treatment reports 1987;71(6):609-13.
1987: A R Hanauske; C Kent Osborne; Gary C Chamness; Gary M Clark; B J Forseth; J B Buchok; Carlos L Arteaga; Daniel Von Hoff
Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agents.
European journal of cancer & clinical oncology 1987;23(5):545-51.
1987: Daniel Von Hoff
In vitro predictive testing: the sulfonamide era.
International journal of cell cloning 1987;5(3):179-90.
1987: T D Brown; J Koeller; K Beougher; J Golando; E M Bonnem; R J Spiegel; Daniel Von Hoff
A phase I clinical trial of recombinant DNA gamma interferon.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(5):790-8.
1987: S M Carroll; Patrick Gaudray; Margaret De Rose; J F Emery; J L Meinkoth; E Nakkim; M Subler; Daniel Von Hoff; G M Wahl
Characterization of an episome produced in hamster cells that amplify a transfected CAD gene at high frequency: functional evidence for a mammalian replication origin.
Molecular and cellular biology 1987;7(5):1740-50.
1987: L Balducci; B Blumenstein; Daniel Von Hoff; M Davis; H E Hynes; R M Bukowski; E D Crawford
Evaluation of fludarabine phosphate in renal cell carcinoma: a Southwest Oncology Group Study.
Cancer treatment reports 1987;71(5):543-4.
1987: U Hanauske; A R Hanauske; M H Marshall; V A Muggia; Daniel Von Hoff
Biphasic effect of vanadium salts on in vitro tumor colony growth.
International journal of cell cloning 1987;5(2):170-8.
1987: Daniel Von Hoff
Whither carboplatin?--A replacement for or an alternative to cisplatin?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(2):169-71.
1987: John Kuhn; C E Balmer; T M Ludden; D M Loesch; Daniel Von Hoff; J F Bender; A J Grillo-Lopez
Pharmacokinetics of ametantrone acetate (NSC-287513).
Cancer chemotherapy and pharmacology 1987;19(2):133-7.
1987: S W Mamber; J D Mitulski; K L Hamelehle; J C French; G C Hokanson; J L Shillis; Wilbur R Leopold; Daniel Von Hoff; J B Tunac
Biological effects of acetomycin. I. Activity against tumor cells in vitro and in vivo.
The Journal of antibiotics 1987;40(1):73-6.
1987: A R Hanauske; J Buchok; W Scheithauer; Daniel Von Hoff
Human colon cancer cell lines secrete alpha TGF-like activity.
British journal of cancer 1987;55(1):57-9.
1987: G R Weiss; Carlos L Arteaga; T D Brown; J B Craig; G S Harman; J M Koeller; John Kuhn; Daniel Von Hoff
New anticancer agents.
Cancer chemotherapy and biological response modifiers 1987;9():93-120.
1986: W Scheithauer; G M Clark; S E Salmon; W Dorda; R H Shoemaker; Daniel Von Hoff
Model for estimation of clinically achievable plasma concentrations for investigational anticancer drugs in man.
Cancer treatment reports 1986;70(12):1379-82.
1986: D E Merkel; N L Griffin; K Kagan-Hallet; Daniel Von Hoff
Central nervous system toxicity with fludarabine.
Cancer treatment reports 1986;70(12):1449-50.
1986: Daniel Von Hoff; G M Clark; G R Weiss; M H Marshall; J B Buchok; W A Knight; C F LeMaistre
Use of in vitro dose response effects to select antineoplastics for high-dose or regional administration regimens.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(12):1827-34.
1986: A R Hanauske; J B Buchok; R L Pardue; V A Muggia; Daniel Von Hoff
Assessment of biological activity of linear alpha-transforming growth factor and monospecific antibodies to alpha-transforming growth factor and linear alpha-transforming growth factor.
Cancer research 1986;46(11):5567-70.
1986: G A Sarosy; T D Brown; Daniel Von Hoff; R J Spiegel; J P Golando; K L Beougher; John Kuhn; D L Kisner
Phase I study of alpha 2-interferon plus doxorubicin in patients with solid tumors.
Cancer research 1986;46(10):5368-71.
1986: Daniel Von Hoff; B Forseth; L Gonzales
Culture and sensitivity testing of tumors.
Texas medicine 1986;82(9):32-5.
1986: Daniel Von Hoff; G Sarosy; T D Brown; John Kuhn; D L Kisner
Rationale for and conduct of a phase I clinical trial with interferon alfa-2b plus doxorubicin.
Seminars in oncology 1986;13(3 Suppl 2):72-7.
1986: A R Hanauske; Daniel Von Hoff
The value of the human tumor cloning assay in ovarian cancer.
Clinical obstetrics and gynecology 1986;29(3):638-46.
1986: Daniel Von Hoff; G M Clark; B J Forseth; J D Cowan
Simultaneous in vitro drug sensitivity testing on tumors from different sites in the same patient.
Cancer 1986;58(5):1007-13.
1986: G R Weiss; J Crowley; Daniel Von Hoff; Sarah A Taylor; R J Belt; C A Coltman; H E Hynes; J J Costanzi
Phase II study of fludarabine phosphate for the treatment of advanced non-small cell carcinoma of the lung: a Southwest Oncology Group Study.
Cancer treatment reports 1986;70(9):1123-4.
1986: W Scheithauer; Daniel Von Hoff; G M Clark; J L Shillis; E F Elslager
In vitro activity of the novel antitumor antibiotic fostriecin (CI-920) in a human tumor cloning assay.
European journal of cancer & clinical oncology 1986;22(8):921-6.
1986: Daniel Von Hoff; B J Forseth; M Huong; J B Buchok; B Lathan
Improved plating efficiencies for human tumors cloned in capillary tubes versus Petri dishes.
Cancer research 1986;46(8):4012-7.
1986: T D Shenkenberg; Daniel Von Hoff
Mitoxantrone: a new anticancer drug with significant clinical activity.
Annals of internal medicine 1986;105(1):67-81.
1986: W Scheithauer; G M Clark; M P Moyer; Daniel Von Hoff
New screening system for selection of anticancer drugs for treatment of human colorectal cancer.
Cancer research 1986;46(6):2703-8.
1986: T D Shenkenberg; Daniel Von Hoff
Possible mitoxantrone-induced amenorrhea.
Cancer treatment reports 1986;70(5):659-61.
1986: F A Dorr; Daniel Von Hoff; John Kuhn; R Schwartz; D L Kisner
Phase I clinical investigation of 7-con-O-methylnogaril, a new anthracycline antibiotic.
Cancer research 1986;46(5):2562-5.
1986: Wolfgang E Berdel; Daniel Von Hoff; C Unger; H D Schick; U Fink; A Reichert; H Eibl; J Rastetter
Ether lipid derivatives: antineoplastic activity in vitro and the structure-activity relationship.
Lipids 1986;21(4):301-4.
1986: R D Hilgers; Daniel Von Hoff; R L Stephens; J G Boutselis
Mitoxantrone and advanced squamous cell carcinoma of the cervix: a Southwest Oncology Group Study.
Cancer treatment reports 1986;70(4):527-8.
1986: M R Hersh; W Linn; John Kuhn; Daniel Von Hoff
Electrocardiographic monitoring of patients receiving phase I cancer chemotherapy.
Cancer treatment reports 1986;70(3):349-52.
1986: Nai-Kong V Cheung; Daniel Von Hoff; S E Strandjord; Peter F Coccia
Detection of neuroblastoma cells in bone marrow using GD2 specific monoclonal antibodies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(3):363-9.
1986: W Scheithauer; Daniel Von Hoff; B Forseth; J D Cowan
Direct effects of the hypoxic cell sensitizer misonidazole on colony formation in a human tumor cloning assay.
Cancer drug delivery 1986;3(1):15-24.
1986: Daniel Von Hoff; B J Forseth; J N Turner; G M Clark; L E Warfel
Selection of chemotherapy for patient treatment utilizing a radiometric versus a cloning system.
International journal of cell cloning 1986;4(1):16-26.
1986: G J Harris; Daniel Von Hoff
Drug sensitivity testing of carcinoma of the gallbladder and biliary tree in a human tumor cloning assay.
Cancer drug delivery 1986;3(3):197-204.
1986: G J Harris; J N Turner; Daniel Von Hoff
Growth of carcinoma of the esophagus and gastroesophageal junction in a human tumor cloning assay.
Cancer drug delivery 1986;3(4):273-8.
1986: G L Morris; P M Zeltzer; S L Schneider; Daniel Von Hoff
Cloning of pediatric malignancies for drug sensitivity testing in the human tumor cloning assay.
The American journal of pediatric hematology/oncology 1986;8(1):52-7.
1986: J J Hutton; Daniel Von Hoff
Cytotoxicity of 2-chlorodeoxyadenosine in a human tumor colony-forming assay.
Cancer drug delivery 1986;3(2):115-22.
1986: M R Hersh; John Kuhn; J L Phillips; G Clark; T M Ludden; Daniel Von Hoff
Pharmacokinetic study of fludarabine phosphate (NSC 312887).
Cancer chemotherapy and pharmacology 1986;17(3):277-80.
1985: B Lathan; G M Clark; Daniel Von Hoff
In vitro comparison of vinzolidine and vinblastine: a model for methods of evaluation of analogues in a human tumor cloning system.
Cancer research 1985;45(12 Pt 1):6286-9.
1985: M D Green; J Speyer; J Wernz; D Kisner; J Koeller; Ronald Blum; Daniel Von Hoff; F Muggia
Doxorubicin and interferon: rationale and clinical experience.
Cancer treatment reviews 1985;12 Suppl B():61-7.
1985: A R Hanauske; U Hanauske; Daniel Von Hoff
The human tumor cloning assay in cancer research and therapy: a review with clinical correlations.
Current problems in cancer 1985;9(12):1-66.
1985: R D Hilgers; Daniel Von Hoff; R L Stephens; J G Boutselis; S E Rivkin
Mitoxantrone in adenocarcinoma of the endometrium: a Southwest Oncology Group Study.
Cancer treatment reports 1985;69(11):1329-30.
1985: B Lathan; D P Edwards; Lynn Dressler; Daniel Von Hoff; W L McGuire
Immunological detection of Chinese hamster ovary cells expressing a multidrug resistance phenotype.
Cancer research 1985;45(10):5064-9.
1985: Daniel Von Hoff
Implications of tumor cell heterogeneity for in vitro drug sensitivity testing.
Seminars in oncology 1985;12(3):327-31.
1985: G J Harris; J Zeagler; Daniel Von Hoff
A method for performing scanning electron microscopy of colonies growing in a human tumor cloning system.
International journal of cell cloning 1985;3(5):286-93.
1985: Daniel Von Hoff; B Forseth; L E Warfel
Use of a radiometric system to screen for antineoplastic agents: correlation with a human tumor cloning system.
Cancer research 1985;45(9):4032-8.
1985: G Weiss; Daniel Von Hoff
Human tumor cloning assay: clinical applications for ovarian, gastric, pancreatic, and colorectal cancers.
Seminars in oncology 1985;12(3 Suppl 4):69-74.
1985: T J Melink; Daniel Von Hoff; John Kuhn; M R Hersh; L A Sternson; T F Patton; R Siegler; D H Boldt; Gary M Clark
Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).
Cancer research 1985;45(6):2859-65.
1985: H O Douglass; J M MacIntyre; J Kaufman; Daniel Von Hoff; P F Engstrom; D Klaassen
Eastern Cooperative Oncology Group phase II studies in advanced measurable colorectal cancer. I. Razoxane, Yoshi-864, piperazinedione, and lomustine.
Cancer treatment reports 1985;69(5):543-5.
1985: F E Bull; Daniel Von Hoff; S P Balcerzak; R L Stephens; F J Panettiere
Phase II trial of mitoxantrone in advanced sarcomas: a Southwest Oncology Group study.
Cancer treatment reports 1985;69(2):231-3.
1985: G R Weiss; M Hersh; John Kuhn; T M Ludden; Daniel Von Hoff; D L Kisner; T E Pirtle
A phase I and pharmacokinetic comparison of hepatic arterial and peripheral vein infusions of bisantrene for liver cancer.
Cancer chemotherapy and pharmacology 1985;15(2):144-8.
1985: Sarah A Taylor; B T Tranum; Daniel Von Hoff; J J Costanzi
Phase II trial of 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino 9,10-anthracenedione dihydrochloride)(NSC 301739, DHAD) in patients with metastatic malignant melanoma. A Southwest Oncology Group pilot.
Investigational new drugs 1985;3(1):67-9.
1985: A R Hanauske; Daniel Von Hoff
Clinical correlations with the human tumor cloning assay.
Cancer investigation 1985;3(6):541-51.
1985: J D Cowan; C Kent Osborne; J A Neidhart; Daniel Von Hoff; J J Constanzi; C B Vaughn
A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study).
Investigational new drugs 1985;3(2):149-52.
1985: C Kent Osborne; Daniel Von Hoff; K Mullins
Endocrine therapy testing of human breast cancers in the soft agar clonogenic assay.
Breast cancer research and treatment 1985;6(3):229-35.
1985: K E Hill; Daniel Von Hoff; R F Burk
Effect of inhibition of gamma-glutamyltranspeptidase by AT-125 (acivicin) on glutathione and cysteine levels in rat brain and plasma.
Investigational new drugs 1985;3(1):31-4.
1984: Daniel Von Hoff
Use of daunorubicin in patients with solid tumors.
Seminars in oncology 1984;11(4 Suppl 3):23-7.
1984: D E Mattox; Daniel Von Hoff; W L McGuire
Androgen receptors and antiandrogen therapy for laryngeal carcinoma.
Archives of otolaryngology (Chicago, Ill. : 1960) 1984;110(11):721-4.
1984: R D Hilgers; S E Rivkin; Daniel Von Hoff; D S Alberts
Mitoxantrone in epithelial carcinoma of the ovary. A Southwest Oncology Group study.
American journal of clinical oncology 1984;7(5):499-501.
1984: D H Boldt; Daniel Von Hoff; John Kuhn; M Hersh
Effects on human peripheral lymphocytes of in vivo administration of 9-beta-D-arabinofuranosyl-2-fluoroadenine-5'-monophosphate (NSC 312887), a new purine antimetabolite.
Cancer research 1984;44(10):4661-6.
1984: C A Coltman; T M Coltman; S P Balcerzak; F S Morrison; Daniel Von Hoff
Mitoxantrone in refractory nonHodgkin's lymphoma. A Southwest Oncology Group study.
Seminars in oncology 1984;11(3 Suppl 1):50-3.
1984: J J Hutton; Daniel Von Hoff; John Kuhn; J Phillips; M Hersh; G Clark
Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate (NSC 312887), a new purine antimetabolite.
Cancer research 1984;44(9):4183-6.
1984: Sarah A Taylor; Daniel Von Hoff; Laurence H Baker; S P Balcerzak
Phase II clinical trial of mitoxantrone in patients with advanced renal cell carcinoma: a Southwest Oncology Group study.
Cancer treatment reports 1984;68(6):919-20.
1984: G W Sledge; G M Clark; C Griffin; D E Mattox; Daniel Von Hoff
Phase II trial of vindesine in patients with squamous cell cancer of the head and neck.
American journal of clinical oncology 1984;7(3):209-11.
1984: J W Myers; Daniel Von Hoff; G M Clark; C A Coltman
Phase II clinical trial with bisantrene in patients with advanced refractory small cell lung cancer.
Cancer treatment reports 1984;68(6):927-8.
1984: B Lathan; Daniel Von Hoff; E Elslager
Use of a human tumor cloning system to evaluate analogs of methotrexate and mitoxantrone.
Cancer treatment reports 1984;68(5):733-8.
1984: D E Mattox; Daniel Von Hoff; G M Clark; T B Aufdemorte
Factors that influence growth of head and neck squamous carcinoma in the soft agar cloning assay.
Cancer 1984;53(8):1736-40.
1984: J W Myers; Daniel Von Hoff; John Kuhn; Martin Nusynowitz; A R Benedetto; R Pocelinko
Radioangiocardiogram monitoring in patients receiving bisantrene.
American journal of clinical oncology 1984;7(2):129-30.
1984: Daniel Von Hoff; D A Amato; J H Kaufman; G Falkson; T J Cunningham
Randomized trial of chlorozotocin, neocarzinostatin, or methyl-CCNU in patients with malignant melanoma.
American journal of clinical oncology 1984;7(2):135-9.
1984: G W Sledge; G M Clark; Daniel Von Hoff
Phase II trial of vindesine in adenocarcinoma of the lung.
Cancer treatment reports 1984;68(3):557-8.
1984: A E Bogden; Daniel Von Hoff
Comparison of the human tumor cloning and subrenal capsule assays.
Cancer research 1984;44(3):1087-90.
1984: C Kent Osborne; Daniel Von Hoff; J D Cowan; J Sandbach
Bisantrene, an active drug in patients with advanced breast cancer.
Cancer treatment reports 1984;68(2):357-60.
1984: J D Cowan; Daniel Von Hoff; B Neuenfeldt; G M Mills; G M Clark
Predictive value of trypan blue exclusion viability measurements for colony formation in a human tumor cloning assay.
Cancer drug delivery 1984;1(2):95-100.
1984: B Lathan; Daniel Von Hoff
Cytotoxic activity of echinomycin in a human tumor cloning system.
Cancer drug delivery 1984;1(3):191-8.
1984: D L Kisner; P Mehta; G E Paget; Daniel Von Hoff
Activity of Carbetimer in a human tumor cloning system.
Investigational new drugs 1984;2(1):55-8.
1984: P M Zeltzer; S L Schneider; Daniel Von Hoff
Morphologic, cytochemical and neurochemical characterization of the human medulloblastoma cell line TE671.
Journal of neuro-oncology 1984;2(1):35-45.
1983: C A Coltman; T M McDaniel; S P Balcerzak; F S Morrison; Daniel Von Hoff
Mitoxantrone hydrochloride in lymphoma.
Cancer treatment reviews 1983;10 Suppl B():73-6.
1983: C Kent Osborne; A Drelichman; Daniel Von Hoff; E D Crawford
Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer.
Cancer treatment reports 1983;67(12):1133-5.
1983: D E Mattox; Daniel Von Hoff; L L Harris
Human tumor cloning assay in advanced head and neck cancer. Prospective correlative trial.
Archives of otolaryngology (Chicago, Ill. : 1960) 1983;109(11):724-6.
1983: D M Loesch; Daniel Von Hoff; John Kuhn; C A Coltman; F Tio; T K Chaudhuri; J F Bender; A J Grillo-Lopez
Phase I investigation of ametantrone.
Cancer treatment reports 1983;67(11):987-91.
1983: M F Sarosdy; Daniel Von Hoff
Prediction of response to cancer chemotherapy.
Drugs 1983;26(5):454-9.
1983: C M Kitten; Daniel Von Hoff; E V Bennett; J K Trinkle; F L Grover
The human tumor clonogenic assay in the treatment of patients with lung cancer.
The Annals of thoracic surgery 1983;36(4):408-10.
1983: J T Casper; Jeffrey M. Trent; J Harb; V Piaskowski; M Helmsworth; J Finlan; Daniel Von Hoff
Distinguishing characteristics of a new neuroblastoma cell line.
Cancer genetics and cytogenetics 1983;10(2):177-86.
1983: D E Mattox; L A Sternson; Daniel Von Hoff; John Kuhn; A J Repta
Tumor concentration of platinum in patients with head and neck cancer.
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 1983;91(3):271-5.
1983: H R Metelmann; Daniel Von Hoff
In vitro activation of dacarbazine (DTIC) for a human tumor cloning system.
International journal of cell cloning 1983;1(1):24-32.
1983: Daniel Von Hoff; G M Clark; B J Stogdill; M F Sarosdy; M T O'Brien; J T Casper; D E Mattox; C P Page; A B Cruz; J F Sandbach
Prospective clinical trial of a human tumor cloning system.
Cancer research 1983;43(4):1926-31.
1983: Daniel Von Hoff; T Chen; G M Clark; S K Callahan; R Livingston
Mitoxantrone for treatment of patients with refractory small cell carcinoma of the lung: a Southwest Oncology Group Study.
Cancer treatment reports 1983;67(4):403-4.
1983: Daniel Von Hoff
"Send this patient's tumor for culture and sensitivity".
The New England journal of medicine 1983;308(3):154-5.
1983: John Kuhn; T M Ludden; J W Myers; Daniel Von Hoff
Characterization of the pharmacokinetics of bisantrene (NSC-337766).
Investigational new drugs 1983;1(3):253-7.
1983: W A Knight; Daniel Von Hoff; J A Neidhart; B L Tranum; C Fabian; Stephen E Jones
Mitoxantrone in advanced breast cancer: a phase II trial of the Southwest Oncology Group.
Investigational new drugs 1983;1(2):181-4.
1983: J D Cowan; Daniel Von Hoff; G M Clark
Comparative cytotoxicity of adriamycin, mitoxantrone and bisantrene as measured by a human tumor cloning system.
Investigational new drugs 1983;1(2):139-44.
1983: J W Myers; Daniel Von Hoff; John Kuhn; C Kent Osborne; J F Sandbach; R Pocelinko
Anaphylactoid reactions associated with bisantrene infusions.
Investigational new drugs 1983;1(1):85-8.
1983: C A Coltman; T M McDaniel; S P Balcerzak; F S Morrison; Daniel Von Hoff
Mitoxantrone hydrochloride (NSC-310739) in lymphoma. A Southwest Oncology Group study.
Investigational new drugs 1983;1(1):65-70.
1983: H R Metelmann; Daniel Von Hoff
Application of a microsomal drug activation system in a human tumor cloning assay.
Investigational new drugs 1983;1(1):27-32.
1983: J D Cowan; Daniel Von Hoff; A Dinesman; G Clark
Use of a human tumor cloning system to screen retinoids for antineoplastic activity.
Cancer 1983;51(1):92-6.
1982: Arlene A Forastiere; S M Crain; K Callahan; David A Van Echo; D Mattox; M Thant; Daniel Von Hoff; P H Wiernik
Phase II trial of aziridinylbenzoquinone (AZQ) in head and neck cancer.
Cancer treatment reports 1982;66(12):2097-8.
1982: J W Myers; Daniel Von Hoff; C A Coltman; John Kuhn; David A Van Echo; S Rivkin; R Pocelinko
Phase II evaluation of bisantrene in patients with renal cell carcinoma.
Cancer treatment reports 1982;66(10):1869-71.
1982: J Sandbach; Daniel Von Hoff; G Clark; A B Cruz; M Obrien
Direct cloning of human breast cancer in soft agar culture.
Cancer 1982;50(7):1315-21.
1982: M F Sarosdy; D L Lamm; H M Radwin; Daniel Von Hoff
Clonogenic assay and in vitro chemosensitivity testing of human urologic malignancies.
Cancer 1982;50(7):1332-8.
1982: J D Cowan; Daniel Von Hoff; B McDonald; R W Talley; J D McCracken; T Chen
Phase II trial of mitoxantrone in previously untreated patients with colorectal adenocarcinoma: A Southwest Oncology Group Study.
Cancer treatment reports 1982;66(9):1779-80.
1982: B K Bhuyan; K A Newell; S L Crampton; Daniel Von Hoff
CC-1065 (NSC 298223), a most potent antitumor agent: kinetics of inhibition of growth, DNA synthesis, and cell survival.
Cancer research 1982;42(9):3532-7.
1982: G J Harris; J Zeagler; A Hodach; J Casper; J Harb; Daniel Von Hoff
Ultrastructural analysis of colonies growing in a human tumor cloning system.
Cancer 1982;50(4):722-6.
1982: Daniel Von Hoff; B Forseth; H R Metelmann; G Harris; S Rowan; C A Coltman
Direct cloning of human malignant melanoma.
Cancer 1982;50(4):696-701.
1982: J P McGovren; J C Stewart; G L Elfring; R B Smith; N Soares; J H Wood; David G Poplack; Daniel Von Hoff
Plasma and cerebrospinal fluid pharmacokinetics of acivicin in Ommaya reservoir-bearing rhesus monkeys.
Cancer treatment reports 1982;66(6):1333-41.
1982: Daniel Von Hoff; M Rozencweig; M Piccart
The cardiotoxicity of anticancer agents.
Seminars in oncology 1982;9(1):23-33.
1982: C M Kitten; Daniel Von Hoff; E V Bennett; F L Grover
Growth of lung cancer in a human tumor clonogenic system.
The Journal of thoracic and cardiovascular surgery 1982;83(3):363-71.
1982: Daniel Von Hoff; kenneth d swenerton; L Hetanen; E Gafney; S Rivkin; S Schuchart; C A Coltman
Long-distance transportation of specimens for human tumor cloning.
Stem cells 1982;2(2):122-8.
1982: D L Elson; C Kent Osborne; R B Livingston; Daniel Von Hoff
Methods for determining chemosensitivity of MCF-7 cells in double-layer agar culture: labeling index depression and colony count inhibition.
Stem cells 1982;2(1):34-44.
1982: Daniel Von Hoff; J Gutterman; B Portnoy; C A Coltman
Activity of human leukocyte interferon in a human tumor cloning system.
Cancer chemotherapy and pharmacology 1982;8(1):99-103.
1981: S E Salmon; Daniel Von Hoff
In vitro evaluation of anticancer drugs with the human tumor stem cell assay.
Seminars in oncology 1981;8(4):377-85.
1981: B M Mullen; D E Mattox; Daniel Von Hoff; E M Hearne
The effect of preoperative adriamycin and dihydroxyanthracenedione on wound healing.
The Laryngoscope 1981;91(9 Pt 1):1436-43.
1981: Daniel Von Hoff; J W Myers; John Kuhn; J F Sandbach; R Pocelinko; G Clark; C A Coltman
Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone] dihydrochloride (CL216,942).
Cancer research 1981;41(8):3118-21.
1981: Daniel Von Hoff; L M Weisenthal; D C Ihde; M J Mathews; M Layard; R Makuch
Growth of lung cancer colonies from bronchoscopy washings.
Cancer 1981;48(2):400-3.
1981: Daniel Von Hoff; J Casper; E Bradley; J Sandbach; D Jones; R Makuch
Association between human tumor colony-forming assay results and response of an individual patient's tumor to chemotherapy.
The American journal of medicine 1981;70(5):1027-41.
1981: Daniel Von Hoff; C A Coltman; B Forseth
Activity of mitoxantrone in a human tumor cloning system.
Cancer research 1981;41(5):1853-5.
1981: Daniel Von Hoff; D Howser; B J Lewis; J Holcenberg; R B Weiss; R C Young
Phase I study of ICRF-187 using a daily for 3 days schedule.
Cancer treatment reports 1981;65(3-4):249-52.
1981: E B Pollard; F Tio; J W Myers; G Clark; C A Coltman; Daniel Von Hoff
Utilization of a human tumor cloning system to monitor for marrow involvement with small cell carcinoma of the lung.
Cancer research 1981;41(3):1015-20.
1981: D F Chiuten; M Rozencweig; Daniel Von Hoff; F M Muggia
Clinical trials with the hexitol derivatives in the U.S.
Cancer 1981;47(3):442-51.
1981: Daniel Von Hoff; J Sandbach; C Kent Osborne; C Metelmann; G M Clark; M O'Brien
Potential and problems with growth of breast cancer in a human tumor cloning system.
Breast cancer research and treatment 1981;1(2):141-8.
1981: Daniel Von Hoff; J Cowan; G Harris; G Reisdorf
Human tumor cloning: feasibility and clinical correlations.
Cancer chemotherapy and pharmacology 1981;6(3):265-71.
1981: Daniel Von Hoff; C A Coltman; B Forseth
Activity of 9-10 anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone]dihydrochloride (CL216,942) in a human tumor cloning system. Leads for phase II trials in man.
Cancer chemotherapy and pharmacology 1981;6(2):141-4.
1981: Daniel Von Hoff; John Kuhn; G Clark
Does color of an antitumor agent predict for clinical antitumor activity?
Cancer chemotherapy and pharmacology 1981;6(1):93-4.
1981: D T Vistica; Daniel Von Hoff; B Torain
Uptake of melphalan by human ovarian carcinoma cells and its relationship to the amino acid content of ascitic fluid.
Cancer treatment reports 1981;65(1-2):157-61.
1981: Daniel Von Hoff; M Layard
Risk factors for development of daunorubicin cardiotoxicity.
Cancer treatment reports 1981;65 Suppl 4():19-23.
1981: M Rozencweig; R Abele; Daniel Von Hoff; F M Muggia
Cisplatin: impact of a new anticancer agent on current therapeutic strategies.
Anticancer research 1981;1(4):199-204.
1981: M Rozencweig; Daniel Von Hoff; M J Staquet; P S Schein; J S Penta; A Goldin; F M Muggia; E J Freireich; V T DeVita
Animal toxicology for early clinical trials with anticancer agents.
Cancer clinical trials 1981;4(1):21-8.
1981: D L Glaubiger; Daniel Von Hoff; J S Holcenberg; Barton A. Kamen; C Pratt; R S Ungerleider
The relative tolerance of children and adults to anticancer drugs.
Frontiers of radiation therapy and oncology 1981;16():42-9.
1981: J Z Fuks; David A Van Echo; Joseph Aisner; Daniel Von Hoff; P H Wiernik
Phase II trial of AMSA in patients with refractory small cell carcinoma of the lung.
Cancer treatment reports 1981;65(1-2):133-4.
1981: Daniel Von Hoff; D S Alberts; D E Mattox; S Coulthard; B Dana; M Manning; J W Myers; C B Griffin
Combination chemotherapy with cisplatin, bleomycin, and methotrexate in patients with advanced head and neck cancer.
Cancer clinical trials 1981;4(2):215-8.
1980: D E Mattox; Daniel Von Hoff
Culture of human head and neck cancer stem cells using soft agar.
Archives of otolaryngology (Chicago, Ill. : 1960) 1980;106(11):672-4.
1980: E C Bradley; C M Reichert; Murray F Brennan; Daniel Von Hoff
Direct cloning of human parathyroid hyperplasia cells in soft-agar culture.
Cancer research 1980;40(10):3694-6.
1980: D E Mattox; Daniel Von Hoff
In vitro stem cell assay in head and neck squamous carcinoma.
American journal of surgery 1980;140(4):527-30.
1980: Daniel Von Hoff; J Casper; E Bradley; Jeffrey M. Trent; A Hodach; C Reichert; R Makuch; A Altman
Direct cloning of human neuroblastoma cells in soft agar culture.
Cancer research 1980;40(10):3591-7.
1980: Daniel Von Hoff; E Pollard; John Kuhn; E Murray; C A Coltman
Phase I clinical investigation of 1,4-dihydroxy-5,8-bis (( (2-[(2-hydroxyethyl)amino]ethyl) amino))-9,10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione.
Cancer research 1980;40(5):1516-8.
1980: Daniel Von Hoff; N Soares; P Gormley; David G Poplack
Pharmacokinetics of ICRF-187 in the cerebrospinal fluid of subhuman primates.
Cancer treatment reports 1980;64(4-5):734-6.
1980: Daniel Von Hoff; D Elson; G Polk; C Coltman
Acute ventricular fibrillation and death during infusion of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA).
Cancer treatment reports 1980;64(2-3):356-8.
1980: M Rozencweig; R Abele; M Piccart; Daniel Von Hoff; F M Muggia
N-(Phosphonacetyl)-L-aspartate (PALA): current status.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1980;74():72-7.
1980: Daniel Von Hoff; G J Harris; G Johnson; D Glaubiger
Initial experience with the human tumor stem cell assay system: potential and problems.
Progress in clinical and biological research 1980;48():113-24.
1980: J T Casper; Jeffrey M. Trent; Daniel Von Hoff
Cloning of human neuroblastoma cells in soft agar.
Progress in clinical and biological research 1980;48():101-11.
1980: B E Kressner; R R Morton; A E Martens; S E Salmon; Daniel Von Hoff; B Soehnlen
Use of an image analysis system to count colonies in stem cell assays of human tumors.
Progress in clinical and biological research 1980;48():179-93.
1980: M Rozencweig; Daniel Von Hoff; J C Allegra; F M Muggia
Surgical adjuvant trials in the United States.
European journal of cancer 1980;Suppl 1():173-7.
1980: Daniel Von Hoff; L Weisenthal
In vitro methods to predict for patient response to chemotherapy.
Advances in pharmacology and chemotherapy 1980;17():133-56.
1980: M Rozencweig; Daniel Von Hoff; Sewa S Legha; R L Cysyk; F M Muggia
m-AMSA: a new anticancer agent.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1980;74():250-7.
1980: G Falkson; Daniel Von Hoff; D Klaassen; H Du Plessis; C F Van Der Merwe; A M Van Der Merwe; P P Carbone
A phase II study of neocarzinostatin (NSC 157365) in malignant hepatoma. An Eastern Cooperative Oncology Group pilot study.
Cancer chemotherapy and pharmacology 1980;4(1):33-6.
1979: M J Staquet; M Rozencweig; Daniel Von Hoff; F M Muggia
The delta and epsilon errors in the assessment of cancer clinical trials.
Cancer treatment reports 1979;63(11-12):1917-21.
1979: Daniel Von Hoff; M W Layard; P Basa; H L Davis; A L Von Hoff; M Rozencweig; F M Muggia
Risk factors for doxorubicin-induced congestive heart failure.
Annals of internal medicine 1979;91(5):710-7.
1979: R C Young; Daniel Von Hoff; P Gormley; R Makuch; J Cassidy; D Howser; J M Bull
cis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer.
Cancer treatment reports 1979;63(9-10):1539-44.
1979: Daniel Von Hoff; R Schilsky; C M Reichert; R L Reddick; M Rozencweig; R C Young; F M Muggia
Toxic effects of cis-dichlorodiammineplatinum(II) in man.
Cancer treatment reports 1979;63(9-10):1527-31.
1979: Daniel Von Hoff; M Rozencweig; F M Muggia
The evaluation of cytotoxic drugs.
Cancer treatment reviews 1979;6 Suppl():1-8.
1979: R Catane; Daniel Von Hoff; D L Glaubiger; F M Muggia
Azaserine, DON, and azotomycin: three diazo analogs of L-glutamine with clinical antitumor activity.
Cancer treatment reports 1979;63(6):1033-8.
1979: M Rozencweig; C De Sloover; Daniel Von Hoff; H J Tagnon; F M Muggia
Anthracycline derivatives in new drug development programs.
Cancer treatment reports 1979;63(5):807-8.
1979: M Rozencweig; Daniel Von Hoff; R L Cysyk; F M Muggia
m-AMSA and PALA: two new agents in cancer chemotherapy.
Cancer chemotherapy and pharmacology 1979;3(3):135-41.
1979: Daniel Von Hoff; M Rozencweig
cis-Diamminedichloroplatinum(II): a metal complex with significant anticancer activity.
Advances in pharmacology and chemotherapy 1979;16():273-98.
1978: M Rozencweig; Marvin Zelen; Daniel Von Hoff; F M Muggia
Sounding board. Waiting for a bus: Does it explain age-dependent differences in response to chemotherapy of early breast cancer?
The New England journal of medicine 1978;299(24):1363-4.
1978: Daniel Von Hoff; N Reed Dunnick
The case of the triangular foreign body.
JAMA : the journal of the American Medical Association 1978;240(19):2044-5.
1978: Daniel Von Hoff; K Howser; P Gormley; R A Bender; D Glaubiger; A S Levine; R C Young
Phase I study of methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]-(m-AMSA) using a single-dose schedule.
Cancer treatment reports 1978;62(10):1421-6.
1978: Daniel Von Hoff; M Rozencweig; A C Louie; R A Bender; F M Muggia
"Single"-agent activity of high-dose methotrexate with citrovorum factor rescue.
Cancer treatment reports 1978;62(2):233-5.
1978: H L Davis; Daniel Von Hoff
Evaluation and role of single chemotherapeutic agents in adult non-Hodgkin's lymphoma.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1978;65():129-44.
1978: Daniel Von Hoff; M Rozencweig; M Slavik
Daunomycin: an anthracycline antibiotic effective in acute leukemia.
Advances in pharmacology and chemotherapy 1978;15():1-50.
1978: M Rozencweig; Daniel Von Hoff; A C Louie; F M Muggia
Current trends and prospects in surgical adjuvant trials.
Archiv für Geschwulstforschung 1978;48(7):673-9.
1978: A C Louie; M Rozencweig; Daniel Von Hoff; F M Muggia
Effective adjuvant treatments. A brief review of U.S. clinical trials.
Archiv für Geschwulstforschung 1978;48(7):653-8.
1978: H L Davis; Daniel Von Hoff; J E Henney; M Rozencweig
The role of antitumor antibiotics in current oncologic practice.
Cancer chemotherapy and pharmacology 1978;1(2):83-90.
1978: H L Davis; Daniel Von Hoff; J E Henney; M Rozencweig
Role of antitumor antibiotics in current oncologic practice.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1978;63():21-9.
1977: Daniel Von Hoff; M Rozencweig; F M Muggia
Cytembena: an anticancer drug with an unique structure.
Biomedicine / [publiée pour l'A.A.I.C.I.G.] 1977;26(6):388-92.
1977: M Rozencweig; Daniel Von Hoff; F M Muggia
Investigational chemotherapeutic agents in head and neck cancer.
Seminars in oncology 1977;4(4):425-9.
1977: R E Bellet; M Rozencweig; Daniel Von Hoff; J S Penta; T H Wasserman; F M Muggia
ICRF-159: current status and clinical prospects.
European journal of cancer 1977;13(11):1293-8.
1977: Daniel Von Hoff; M Layard; M Rozencweig; F M Muggia
Time relationship between last dose of daunorubicin and congestive heart failure.
Cancer treatment reports 1977;61(7):1411-3.
1977: Daniel Von Hoff; M Rozencweig; W T Soper; Lee Helman; J S Penta; H L Davis; F M Muggia
Whatever happened to NSC--? An analysis of clinical results of discontinued anticancer agents.
Cancer treatment reports 1977;61(5):759-68.
1977: J S Penta; Daniel Von Hoff; F M Muggia
Hepatotoxicity of combination chemotherapy for acute myelocytic leukemia.
Annals of internal medicine 1977;87(2):247-8.
1977: M Rozencweig; Daniel Von Hoff; J E Henney; F M Muggia
VM 26 and VP 16-213: a comparative analysis.
Cancer 1977;40(1):334-42.
1977: Daniel Von Hoff; J S Penta; Lee Helman; M Slavik
Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration.
Cancer treatment reports 1977;61(4):745-8.
1977: M Rozencweig; Daniel Von Hoff; M Slavik; F M Muggia
Cis-diamminedichloroplatinum (II). A new anticancer drug.
Annals of internal medicine 1977;86(6):803-12.
1977: A Louie; Daniel Von Hoff; M Rozencweig; F Muggia
Adjuvant chemotherapy: correct advice.
JAMA : the journal of the American Medical Association 1977;237(16):1691.
1977: Daniel Von Hoff; M Rozencweig; M Slavik; F M Muggia
Estramustine phosphate: a specific chemotherapeutic agent?.
The Journal of urology 1977;117(4):464-6.
1977: S W Mikulski; Daniel Von Hoff; M Rozencweig; F M Muggia
Tuftsin - unimportant or forgotten.
The New England journal of medicine 1977;296(8):454.
1977: Daniel Von Hoff; M Rozencweig; M Layard; M Slavik; F M Muggia
Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases.
The American journal of medicine 1977;62(2):200-8.
1977: Daniel Von Hoff; M Slavik
5-azacytidine--a new anticancer drug with significant activity in acute myeloblastic leukemia.
Advances in pharmacology and chemotherapy 1977;14():285-326.
1976: Daniel Von Hoff; M Rozencweig; M Slavik; F M Muggia
Activity of daunomycin in solid tumors.
JAMA : the journal of the American Medical Association 1976;236(15):1693.
1976: Daniel Von Hoff; M Slavik; F M Muggia
5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia.
Annals of internal medicine 1976;85(2):237-45.
1976: Daniel Von Hoff; M Slavik; F M Muggia
Letter: Allergic reactions to cis platinum.
Lancet 1976;1(7950):90.
1976: Sewa S Legha; Daniel Von Hoff; M Rozencweig; D Abraham; M Slavik; M Muggia
Neocarzinostatin (NSC 157365) a new cancerostatic compound.
Oncology 1976;33(5-6):265-70.
1975: Daniel Von Hoff; M Luckey; J Wallace; Faith T Fitzgerald
Herpes type 2 meningitis following herpes progenitalis.
The Western journal of medicine 1975;123(6):490-1.
1975: Daniel Von Hoff; V LiVolsi
Diagnostic reliability of needle biopsy of the parietal pleura. A review of 272 biopsies.
American journal of clinical pathology 1975;64(2):200-3.
1974: Daniel Von Hoff; R S Kimball
Letter: Eikenella corrodens infection.
Annals of internal medicine 1974;81(2):273-4.